Glucocorticoid-mediated	O
repression	O
of	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	O
arteritis-SCID	B-protein
chimeras	I-protein
.	O

Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large-sized	O
arteries	O
.	O

Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

GCA	O
is	O
self-sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O

Administration	O
of	O
dexamethasone	O
to	O
temporal	B-cell_line
artery-SCID	I-cell_line
chimeras	I-cell_line
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	O
tissue	O
concentrations	O
of	O
IL-2	B-RNA
,	I-RNA
IL-1beta	I-RNA
,	I-RNA
and	I-RNA
IL-6	I-RNA
mRNA	I-RNA
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	B-protein
synthase	I-protein
.	O

In	O
contrast	O
,	O
synthesis	O
of	O
IFN-gamma	B-RNA
mRNA	I-RNA
was	O
only	O
slightly	O
decreased	O
,	O
and	O
expression	O
of	O
TGF-beta1	B-protein
was	O
unaffected	O
.	O

These	O
findings	O
correlated	O
with	O
activation	O
of	O
the	O
IkappaBalpha	B-DNA
gene	I-DNA
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	B-protein
in	O
the	O
xenotransplanted	O
tissue	O
.	O

Dose-response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB	B-protein
-mediated	O
cytokine	B-protein
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O

Chronic	O
steroid	O
therapy	O
was	O
able	O
to	O
deplete	O
the	O
T	B-protein
cell	I-protein
products	I-protein
IL-2	B-protein
and	O
IFN-gamma	B-protein
,	O
whereas	O
the	O
activation	O
of	O
tissue-infiltrating	B-cell_type
macrophages	I-cell_type
was	O
only	O
partially	O
affected	O
.	O

IL-1beta	B-protein
transcription	O
was	O
abrogated	O
;	O
in	O
contrast	O
,	O
TGF-beta1	B-RNA
mRNA	I-RNA
synthesis	O
was	O
steroid	O
resistant	O
.	O

The	O
persistence	O
of	O
TGF-beta1-transcribing	B-cell_type
macrophages	I-cell_type
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

Glucocorticoid-mediated	NULL
Repression	NULL
of	NULL
Cytokine	NULL
Gene	NULL
Transcription	NULL
in	NULL
Human	NULL
Arteritis-SCID	NULL
Chimeras	NULL
Alexander	NULL
Brack	NULL
,	NULL
*	NULL
Heike	NULL
L.	NULL
Rittner	NULL
,	NULL
*	NULL
Brian	NULL
R.	NULL
Younge	NULL
,	NULL
*	NULL
Christian	NULL
Kaltschmidt	NULL
,	NULL
$	NULL
Cornelia	NULL
M.	NULL
Weyand	NULL
,	NULL
*	NULL
and	NULL
Jorg	NULL
J.	NULL
Goronzy*	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
Division	NULL
of	NULL
Rheumatology	NULL
,	NULL
and	NULL
*Department	NULL
of	NULL
Ophthalmology	NULL
,	NULL
Mayo	NULL
Clinic	NULL
and	NULL
Foundation	NULL
,	NULL
Rochester	NULL
,	NULL
Minnesota	NULL
55905	NULL
;	NULL
and	NULL
Institute	NULL
of	NULL
Biochemistry	NULL
,	NULL
University	NULL
of	NULL
Freiburg	NULL
,	NULL
Freiburg	NULL
,	NULL
Germany	NULL
Abstract	NULL
Giant	NULL
cell	NULL
arteritis	NULL
(	NULL
GCA	NULL
)	NULL
is	NULL
a	NULL
vasculitic	NULL
syndrome	NULL
that	NULL
preferentially	NULL
affects	NULL
medium	NULL
and	NULL
large-sized	NULL
arteries	NULL
.	NULL

Glucocorticoid	NULL
therapy	NULL
resolves	NULL
clinical	NULL
symptoms	NULL
within	NULL
hours	NULL
to	NULL
days	NULL
,	NULL
but	NULL
therapy	NULL
has	NULL
to	NULL
be	NULL
continued	NULL
over	NULL
several	NULL
years	NULL
to	NULL
prevent	NULL
disease	NULL
relapses	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
and	NULL
how	NULL
glucocorticoids	NULL
affect	NULL
the	NULL
function	NULL
of	NULL
the	NULL
inflammatory	NULL
infiltrate	NULL
or	NULL
why	NULL
the	NULL
disease	NULL
persists	NULL
subclinically	NULL
despite	NULL
chronic	NULL
treatment	NULL
.	NULL

GCA	NULL
is	NULL
self-sustained	NULL
in	NULL
temporal	NULL
arteries	NULL
engrafted	NULL
into	NULL
SCID	NULL
mice	NULL
,	NULL
providing	NULL
a	NULL
model	NULL
in	NULL
which	NULL
the	NULL
mechanisms	NULL
of	NULL
action	NULL
and	NULL
limitations	NULL
of	NULL
glucocorticoid	NULL
therapy	NULL
can	NULL
be	NULL
examined	NULL
in	NULL
vivo	NULL
.	NULL

Administration	NULL
of	NULL
dexamethasone	NULL
to	NULL
temporal	NULL
artery-SCID	NULL
chimeras	NULL
for	NULL
1	NULL
wk	NULL
induced	NULL
a	NULL
partial	NULL
suppression	NULL
of	NULL
T	NULL
cell	NULL
and	NULL
macrophage	NULL
function	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
reduced	NULL
tissue	NULL
concentrations	NULL
of	NULL
IL-2	NULL
,	NULL
IL-1	NULL
$	NULL
B	NULL
,	NULL
and	NULL
IL-6	NULL
mRNA	NULL
,	NULL
and	NULL
by	NULL
the	NULL
diminished	NULL
expression	NULL
of	NULL
inducible	NULL
NO	NULL
synthase	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
synthesis	NULL
of	NULL
IFN-y	NULL
mRNA	NULL
was	NULL
only	NULL
slightly	NULL
decreased	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
TGF-B1	NULL
was	NULL
unaffected	NULL
.	NULL

These	NULL
findings	NULL
correlated	NULL
with	NULL
activation	NULL
of	NULL
the	NULL
IxBa	NULL
gene	NULL
and	NULL
blockade	NULL
of	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFB	NULL
in	NULL
the	NULL
xenotransplanted	NULL
tissue	NULL
.	NULL

Dose-response	NULL
experiments	NULL
suggested	NULL
that	NULL
steroid	NULL
doses	NULL
currently	NULL
used	NULL
in	NULL
clinical	NULL
medicine	NULL
are	NULL
suboptimal	NULL
in	NULL
repressing	NULL
NFkB-mediated	NULL
cytokine	NULL
production	NULL
in	NULL
the	NULL
inflammatory	NULL
lesions	NULL
.	NULL

Chronic	NULL
steroid	NULL
therapy	NULL
was	NULL
able	NULL
to	NULL
deplete	NULL
the	NULL
T	NULL
cell	NULL
products	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
,	NULL
whereas	NULL
the	NULL
activation	NULL
of	NULL
tissue-infiltrating	NULL
macrophages	NULL
was	NULL
only	NULL
partially	NULL
affected	NULL
.	NULL

IL-1B	NULL
transcription	NULL
was	NULL
abrogated	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
TGF-B1	NULL
mRNA	NULL
synthesis	NULL
was	NULL
steroid	NULL
resistant	NULL
.	NULL

The	NULL
persistence	NULL
of	NULL
TGF-B1-transcribing	NULL
macrophages	NULL
,	NULL
despite	NULL
paralysis	NULL
of	NULL
T	NULL
cell	NULL
function	NULL
,	NULL
may	NULL
provide	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
chronicity	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
and	NULL
may	NULL
identify	NULL
a	NULL
novel	NULL
therapeutic	NULL
target	NULL
in	NULL
this	NULL
inflammatory	NULL
vasculopathy	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1997	NULL
.	NULL

99:2842-2850	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
giant	NULL
cell	NULL
arteritis	NULL
«	NULL
vasculitis	NULL
SCID	NULL
mouse	NULL
«	NULL
NFB	NULL
«	NULL
TGF-B	NULL
Introduction	NULL
Giant	NULL
cell	NULL
vasculitis	NULL
(	NULL
GCA	NULL
)	NULL
is	NULL
the	NULL
most	NULL
frequent	NULL
inflammatory	NULL
vasculopathy	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Inflammatory	NULL
infiltrates	NULL
composed	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
multinucleated	NULL
giant	NULL
cells	NULL
accumulate	NULL
in	NULL
the	NULL
Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
J.J.	NULL
Goronzy	NULL
,	NULL
Mayo	NULL
Clinic	NULL
,	NULL
200	NULL
First	NULL
Street	NULL
,	NULL
SW	NULL
,	NULL
Rochester	NULL
,	NULL
MN	NULL
55905	NULL
.	NULL

Phone	NULL
:	NULL
507-284-1650	NULL
;	NULL
FAX	NULL
:	NULL
507-284-1086	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
3	NULL
December	NULL
1996	NULL
and	NULL
accepted	NULL
in	NULL
revised	NULL
form	NULL
28	NULL
March	NULL
1997	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
Volume	NULL
99	NULL
,	NULL
Number	NULL
12	NULL
,	NULL
June	NULL
1997	NULL
,	NULL
2842-2850	NULL
2642	NULL
Brack	NULL
et	NULL
al	NULL
.	NULL

walls	NULL
of	NULL
medium-sized	NULL
and	NULL
large	NULL
arteries	NULL
.	NULL

The	NULL
formation	NULL
of	NULL
inflammatory	NULL
infiltrates	NULL
in	NULL
the	NULL
vessel	NULL
wall	NULL
leads	NULL
to	NULL
destruction	NULL
of	NULL
the	NULL
elastic	NULL
layers	NULL
and	NULL
intimal	NULL
proliferation	NULL
,	NULL
causing	NULL
vessel	NULL
occlusion	NULL
and	NULL
subsequent	NULL
infarction	NULL
.	NULL

The	NULL
feared	NULL
complications	NULL
of	NULL
the	NULL
disease	NULL
include	NULL
blindness	NULL
,	NULL
stroke	NULL
,	NULL
aortic	NULL
arch	NULL
syndrome	NULL
,	NULL
and	NULL
rupture	NULL
of	NULL
aortic	NULL
aneurysms	NULL
.	NULL

Recent	NULL
data	NULL
have	NULL
indicated	NULL
that	NULL
selected	NULL
CD4+	NULL
T	NULL
cells	NULL
undergo	NULL
clonal	NULL
proliferation	NULL
in	NULL
the	NULL
arterial	NULL
wall	NULL
,	NULL
and	NULL
secrete	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

Based	NULL
upon	NULL
their	NULL
functional	NULL
profile	NULL
,	NULL
several	NULL
populations	NULL
of	NULL
CD68+	NULL
macrophages	NULL
have	NULL
been	NULL
distinguished	NULL
in	NULL
the	NULL
vascular	NULL
lesions	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Macrophages	NULL
producing	NULL
IL-1B	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
TGF-B1	NULL
are	NULL
intermingled	NULL
with	NULL
CD4+	NULL
IFN-y+	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
localize	NULL
to	NULL
the	NULL
adventitial	NULL
layer	NULL
of	NULL
the	NULL
inflamed	NULL
artery	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Macrophages	NULL
accumulating	NULL
in	NULL
the	NULL
tunica	NULL
media	NULL
secrete	NULL
metalloproteinases	NULL
,	NULL
and	NULL
are	NULL
likely	NULL
involved	NULL
in	NULL
the	NULL
destruction	NULL
of	NULL
elastic	NULL
membranes	NULL
and	NULL
proliferation	NULL
of	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

Macrophages	NULL
in	NULL
the	NULL
intima	NULL
of	NULL
the	NULL
affected	NULL
arteries	NULL
synthesize	NULL
inducible	NULL
NO	NULL
synthase	NULL
(	NULL
iNOS	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
emerging	NULL
disease	NULL
model	NULL
suggests	NULL
that	NULL
GCA	NULL
is	NULL
a	NULL
T	NULL
cell-driven	NULL
disease	NULL
in	NULL
which	NULL
recognition	NULL
of	NULL
an	NULL
antigen	NULL
residing	NULL
in	NULL
the	NULL
adventitia	NULL
leads	NULL
to	NULL
macrophage	NULL
activation	NULL
and	NULL
the	NULL
release	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
.	NULL

These	NULL
cytokines	NULL
are	NULL
assumed	NULL
to	NULL
facilitate	NULL
the	NULL
acute	NULL
phase	NULL
reaction	NULL
,	NULL
and	NULL
to	NULL
cause	NULL
the	NULL
local	NULL
and	NULL
systemic	NULL
symptoms	NULL
characteristic	NULL
for	NULL
this	NULL
vasculitic	NULL
syndrome	NULL
.	NULL

A	NULL
striking	NULL
feature	NULL
of	NULL
GCA	NULL
is	NULL
its	NULL
explicit	NULL
responsiveness	NULL
to	NULL
glucocorticoids	NULL
.	NULL

Within	NULL
hours	NULL
to	NULL
days	NULL
,	NULL
patients	NULL
are	NULL
improved	NULL
both	NULL
in	NULL
terms	NULL
of	NULL
the	NULL
constitutional	NULL
as	NULL
well	NULL
as	NULL
the	NULL
ischemic	NULL
manifestations	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
the	NULL
prompt	NULL
therapeutic	NULL
re-sponse	NULL
,	NULL
glucocorticoids	NULL
have	NULL
to	NULL
be	NULL
given	NULL
to	NULL
GCA	NULL
patients	NULL
over	NULL
a	NULL
prolonged	NULL
period	NULL
(	NULL
up	NULL
to	NULL
2-3	NULL
yr	NULL
)	NULL
before	NULL
a	NULL
disease	NULL
remission	NULL
can	NULL
be	NULL
sustained	NULL
.	NULL

Since	NULL
this	NULL
vasculitis	NULL
preferentially	NULL
affects	NULL
individuals	NULL
older	NULL
than	NULL
50	NULL
yr	NULL
of	NULL
age	NULL
,	NULL
side	NULL
effects	NULL
of	NULL
chronic	NULL
steroid	NULL
therapy	NULL
are	NULL
considerable	NULL
,	NULL
and	NULL
alternative	NULL
therapeutic	NULL
approaches	NULL
are	NULL
needed	NULL
.	NULL

Understanding	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vivo	NULL
may	NULL
allow	NULL
for	NULL
design	NULL
of	NULL
new	NULL
therapeutic	NULL
approaches	NULL
,	NULL
and	NULL
could	NULL
also	NULL
shed	NULL
light	NULL
on	NULL
pathological	NULL
events	NULL
in	NULL
the	NULL
chronic	NULL
inflammatory	NULL
process	NULL
.	NULL

In	NULL
in	NULL
vitro	NULL
studies	NULL
,	NULL
the	NULL
immunosuppressive	NULL
action	NULL
of	NULL
glucocorticoids	NULL
has	NULL
been	NULL
attributed	NULL
in	NULL
part	NULL
to	NULL
the	NULL
repression	NULL
of	NULL
cytokine	NULL
gene	NULL
transcription	NULL
(	NULL
6-11	NULL
)	NULL
.	NULL

How	NULL
suppression	NULL
of	NULL
cytokine	NULL
production	NULL
affects	NULL
the	NULL
different	NULL
cellular	NULL
components	NULL
of	NULL
the	NULL
inflammatory	NULL
infiltrate	NULL
is	NULL
not	NULL
understood	NULL
.	NULL

In	NULL
vivo	NULL
studies	NULL
in	NULL
affected	NULL
tissues	NULL
are	NULL
necessary	NULL
to	NULL
define	NULL
the	NULL
steroid	NULL
responsiveness	NULL
of	NULL
the	NULL
diverse	NULL
cells	NULL
and	NULL
mediators	NULL
in	NULL
an	NULL
effort	NULL
to	NULL
identify	NULL
those	NULL
elements	NULL
that	NULL
are	NULL
involved	NULL
in	NULL
disease	NULL
relapses	NULL
in	NULL
the	NULL
first	NULL
years	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

To	NULL
address	NULL
these	NULL
ques-tions	NULL
,	NULL
we	NULL
have	NULL
established	NULL
a	NULL
xenotransplant	NULL
model	NULL
of	NULL
GCA	NULL
by	NULL
1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
APDTC	NULL
,	NULL
ammonium	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
;	NULL
GCA	NULL
,	NULL
giant	NULL
cell	NULL
arteritis	NULL
;	NULL
iNOS	NULL
,	NULL
inducible	NULL
nitric	NULL
oxide	NULL
synthase	NULL
;	NULL
NLS	NULL
,	NULL
nuclear	NULL
localization	NULL
sequence	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
.	NULL

engrafting	NULL
temporal	NULL
arteries	NULL
from	NULL
GCA	NULL
patients	NULL
into	NULL
SCID	NULL
mice	NULL
.	NULL

In	NULL
this	NULL
model	NULL
,	NULL
the	NULL
tissue	NULL
inflammatory	NULL
process	NULL
is	NULL
main-tained	NULL
,	NULL
and	NULL
the	NULL
mechanisms	NULL
and	NULL
limitations	NULL
of	NULL
therapeutic	NULL
interventions	NULL
can	NULL
be	NULL
studied	NULL
directly	NULL
.	NULL

Methods	NULL
Patients	NULL
.	NULL

Temporal	NULL
artery	NULL
specimens	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
undergoing	NULL
biopsy	NULL
for	NULL
diagnostic	NULL
purposes	NULL
.	NULL

The	NULL
diagnosis	NULL
of	NULL
GCA	NULL
was	NULL
confirmed	NULL
by	NULL
histopathology	NULL
.	NULL

Specimens	NULL
were	NULL
divided	NULL
into	NULL
three	NULL
to	NULL
four	NULL
fragments	NULL
,	NULL
and	NULL
were	NULL
implanted	NULL
into	NULL
NOD-SCID	NULL
mice	NULL
.	NULL

Mice	NULL
.	NULL

NOD-SCID	NULL
mice	NULL
were	NULL
bred	NULL
in	NULL
a	NULL
barrier	NULL
facility	NULL
under	NULL
germ-free	NULL
conditions	NULL
.	NULL

Mice	NULL
were	NULL
checked	NULL
for	NULL
leakiness	NULL
by	NULL
determining	NULL
serum	NULL
IgG	NULL
by	NULL
ELISA	NULL
.	NULL

Mice	NULL
,	NULL
ages	NULL
5-7	NULL
wk	NULL
,	NULL
were	NULL
anesthetized	NULL
with	NULL
3	NULL
mg	NULL
ketamine	NULL
,	NULL
and	NULL
temporal	NULL
artery	NULL
specimens	NULL
were	NULL
implanted	NULL
sub-cutaneously	NULL
.	NULL

Treatment	NULL
protocols	NULL
.	NULL

Control	NULL
mice	NULL
and	NULL
mice	NULL
assigned	NULL
to	NULL
different	NULL
treatment	NULL
arms	NULL
were	NULL
implanted	NULL
with	NULL
specimens	NULL
from	NULL
the	NULL
same	NULL
patient	NULL
to	NULL
control	NULL
for	NULL
interindividual	NULL
variation	NULL
of	NULL
the	NULL
inflammatory	NULL
response	NULL
.	NULL

In	NULL
the	NULL
short-term	NULL
dose-response	NULL
experiments	NULL
,	NULL
treatment	NULL
was	NULL
started	NULL
3	NULL
wk	NULL
after	NULL
transplantation	NULL
.	NULL

Mice	NULL
received	NULL
either	NULL
500	NULL
pl	NULL
sterile	NULL
PBS	NULL
intraperitoneally	NULL
for	NULL
seven	NULL
consecutive	NULL
days	NULL
,	NULL
or	NULL
dexamethasone	NULL
at	NULL
doses	NULL
of	NULL
0.04	NULL
,	NULL
0.4	NULL
,	NULL
and	NULL
4	NULL
mg/kg	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
the	NULL
long-term	NULL
treatment	NULL
protocol	NULL
,	NULL
treatment	NULL
was	NULL
started	NULL
on	NULL
the	NULL
day	NULL
of	NULL
xenotransplanta-tion	NULL
.	NULL

Mice	NULL
were	NULL
injected	NULL
with	NULL
either	NULL
500	NULL
pl	NULL
sterile	NULL
PBS	NULL
intraperito-neally	NULL
,	NULL
or	NULL
with	NULL
0.4	NULL
mg/kg	NULL
dexamethasone	NULL
for	NULL
28	NULL
consecutive	NULL
days	NULL
.	NULL

Mice	NULL
were	NULL
killed	NULL
at	NULL
the	NULL
completion	NULL
of	NULL
the	NULL
treatment	NULL
period	NULL
,	NULL
and	NULL
implanted	NULL
specimens	NULL
were	NULL
retrieved	NULL
and	NULL
either	NULL
(	NULL
a	NULL
)	NULL
embedded	NULL
into	NULL
OCT	NULL
compound	NULL
for	NULL
histochemical	NULL
analysis	NULL
,	NULL
or	NULL
(	NULL
b	NULL
)	NULL
RNA-extracted	NULL
.	NULL

In	NULL
the	NULL
dithiocarbamate	NULL
treatment	NULL
trial	NULL
,	NULL
treatment	NULL
was	NULL
started	NULL
7	NULL
d	NULL
after	NULL
transplantation	NULL
.	NULL

Mice	NULL
received	NULL
an	NULL
initial	NULL
dose	NULL
of	NULL
150	NULL
wM	NULL
and	NULL
1.5	NULL
mM	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
ammonium	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
(	NULL
AP-DTC	NULL
)	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
and	NULL
three	NULL
maintenance	NULL
doses	NULL
of	NULL
75	NULL
and	NULL
750	NULL
uM	NULL
APDTC	NULL
,	NULL
respectively	NULL
,	NULL
at	NULL
8	NULL
,	NULL
16	NULL
,	NULL
and	NULL
24	NULL
h.	NULL
Control	NULL
mice	NULL
were	NULL
sham-treated	NULL
.	NULL

Mice	NULL
were	NULL
killed	NULL
after	NULL
32	NULL
h	NULL
,	NULL
and	NULL
specimens	NULL
were	NULL
retrieved	NULL
.	NULL

Antibodies	NULL
.	NULL

The	NULL
following	NULL
antibodies	NULL
were	NULL
used	NULL
for	NULL
immunohistochemical	NULL
staining	NULL
:	NULL
polyclonal	NULL
rabbit	NULL
anti-human	NULL
CD3	NULL
Ab	NULL
,	NULL
1:100	NULL
(	NULL
DAKO	NULL
Corp.	NULL
,	NULL
Carpinteria	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
monoclonal	NULL
mouse	NULL
anti-human	NULL
CD68	NULL
(	NULL
KP-1	NULL
)	NULL
Ab	NULL
,	NULL
1:250	NULL
(	NULL
DAKO	NULL
)	NULL
;	NULL
polyclonal	NULL
rabbit	NULL
anti-human	NULL
iNOS	NULL
Ab	NULL
,	NULL
1:400	NULL
(	NULL
Affinity	NULL
Bioreagents	NULL
,	NULL
Golden	NULL
,	NULL
CO	NULL
)	NULL
;	NULL
monoclonal	NULL
mouse	NULL
anti-human	NULL
TGF-B1	NULL
Ab	NULL
,	NULL
1:100	NULL
(	NULL
Antigenix	NULL
America	NULL
,	NULL
Franklin	NULL
Square	NULL
,	NULL
NY	NULL
)	NULL
;	NULL
mouse	NULL
anti-human	NULL
Rel-A	NULL
nuclear	NULL
localization	NULL
sequence	NULL
(	NULL
NLS	NULL
)	NULL
mAb	NULL
,	NULL
1:150	NULL
;	NULL
biotinylated	NULL
rabbit	NULL
anti-mouse	NULL
mAb	NULL
,	NULL
1:200	NULL
;	NULL
biotinylated	NULL
swine	NULL
anti-rabbit	NULL
mAb	NULL
,	NULL
1:200	NULL
;	NULL
and	NULL
streptavidin	NULL
peroxidase	NULL
(	NULL
all	NULL
DAKO	NULL
)	NULL
.	NULL

Immunohistochemistry	NULL
.	NULL

OCT-embedded	NULL
temporal	NULL
artery	NULL
specimens	NULL
were	NULL
cut	NULL
into	NULL
5-m	NULL
sections	NULL
,	NULL
dried	NULL
in	NULL
a	NULL
37°C	NULL
desiccator	NULL
,	NULL
and	NULL
ace-tone-fixed	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Slides	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
%	NULL
paraformalde-hyde	NULL
for	NULL
3	NULL
min	NULL
,	NULL
and	NULL
endogenous	NULL
peroxidase	NULL
was	NULL
blocked	NULL
with	NULL
0.3	NULL
%	NULL
H	NULL
,	NULL
O	NULL
;	NULL
in	NULL
sodium	NULL
azide	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
reduced	NULL
by	NULL
incubation	NULL
with	NULL
5	NULL
%	NULL
normal	NULL
goat	NULL
serum	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Slides	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
primary	NULL
antibody	NULL
and	NULL
with	NULL
the	NULL
corresponding	NULL
secondary	NULL
antibody	NULL
for	NULL
30	NULL
min	NULL
each	NULL
.	NULL

Anti-CD3	NULL
and	NULL
anti-CD68	NULL
stains	NULL
were	NULL
developed	NULL
with	NULL
streptavidin	NULL
peroxidase	NULL
and	NULL
aminoethylcearbazole	NULL
and	NULL
di-aminobenzidine	NULL
,	NULL
respectively	NULL
.	NULL

Anti-Rel-A	NULL
NLS	NULL
and	NULL
anti-TGF-B1	NULL
stains	NULL
were	NULL
developed	NULL
according	NULL
to	NULL
the	NULL
specifications	NULL
of	NULL
the	NULL
manufacturer	NULL
(	NULL
Vectastain	NULL
immunofluorescent	NULL
red	NULL
kit	NULL
;	NULL
Vector	NULL
Laboratories	NULL
Inc.	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

All	NULL
slides	NULL
were	NULL
counterstained	NULL
with	NULL
hematox-ylin	NULL
for	NULL
1	NULL
min	NULL
,	NULL
and	NULL
were	NULL
mounted	NULL
with	NULL
Permount	NULL
(	NULL
Baxter	NULL
Scientific	NULL
,	NULL
Deerfield	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Negative	NULL
controls	NULL
were	NULL
stained	NULL
without	NULL
the	NULL
primary	NULL
antibody	NULL
,	NULL
and	NULL
photographs	NULL
were	NULL
taken	NULL
(	NULL
Axiphot	NULL
microscope	NULL
;	NULL
Zeiss	NULL
,	NULL
Oberkochen	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Positive	NULL
cells	NULL
were	NULL
counted	NULL
,	NULL
and	NULL
the	NULL
tissue	NULL
area	NULL
of	NULL
each	NULL
counted	NULL
slide	NULL
was	NULL
quantified	NULL
by	NULL
algorithms	NULL
(	NULL
IBAS	NULL
image	NULL
analysis	NULL
system	NULL
;	NULL
Kontron	NULL
Elektronik	NULL
,	NULL
Eching	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Results	NULL
were	NULL
expressed	NULL
as	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
per	NULL
tissue	NULL
area	NULL
.	NULL

PCR	NULL
primers	NULL
and	NULL
biotinylated	NULL
probes	NULL
.	NULL

Primes	NULL
and	NULL
probes	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
B-actin	NULL
(	NULL
5	NULL
'	NULL
:	NULL
ATG	NULL
GCC	NULL
ACG	NULL
GCT	NULL
GCT	NULL
TCC	NULL
AGC	NULL
;	NULL
3	NULL
'	NULL
:	NULL
CAT	NULL
GGT	NULL
GGT	NULL
GCC	NULL
GCC	NULL
AGA	NULL
CAG	NULL
;	NULL
probe	NULL
:	NULL
TAC	NULL
AGG	NULL
TCT	NULL
TTG	NULL
CGG	NULL
ATG	NULL
TC	NULL
)	NULL
,	NULL
IL-18	NULL
(	NULL
5	NULL
'	NULL
:	NULL
GAC	NULL
ACA	NULL
TGG	NULL
GAT	NULL
AAC	NULL
GAG	NULL
GC	NULL
;	NULL
3	NULL
``	NULL
:	NULL
GGG	NULL
ATC	NULL
TAC	NULL
ACT	NULL
CTC	NULL
CAG	NULL
CTG	NULL
;	NULL
probe	NULL
:	NULL
AGC	NULL
TTT	NULL
TTT	NULL
GCT	NULL
GTG	NULL
AGT	NULL
CCC	NULL
GGA	NULL
G	NULL
)	NULL
,	NULL
IL-2	NULL
(	NULL
5	NULL
:	NULL
AAC	NULL
ACA	NULL
GCT	NULL
ACA	NULL
ACT	NULL
GGA	NULL
GC	NULL
;	NULL
3	NULL
'	NULL
:	NULL
AGA	NULL
CTT	NULL
GTC	NULL
TAC	NULL
CTA	NULL
ATG	NULL
GA	NULL
;	NULL
probe	NULL
:	NULL
AGC	NULL
TAA	NULL
ATT	NULL
TAG	NULL
CAC	NULL
TTC	NULL
CTC	NULL
CAG	NULL
)	NULL
,	NULL
IL-6	NULL
(	NULL
5	NULL
:	NULL
GAT	NULL
GTA	NULL
GCC	NULL
GCC	NULL
CCA	NULL
CAC	NULL
AGA	NULL
CAG	NULL
;	NULL
3	NULL
``	NULL
:	NULL
CCT	NULL
CAA	NULL
ACT	NULL
CCA	NULL
AAA	NULL
GAC	NULL
GAC	NULL
CAG	NULL
TGA	NULL
TG	NULL
;	NULL
probe	NULL
:	NULL
GAG	NULL
AAA	NULL
GGA	NULL
GAC	NULL
ATG	NULL
TAA	NULL
CA	NULL
)	NULL
,	NULL
TGF-B1	NULL
(	NULL
5	NULL
:	NULL
AAG	NULL
TGG	NULL
ACA	NULL
TCA	NULL
ACG	NULL
GGT	NULL
TCA	NULL
CTA	NULL
;	NULL
3	NULL
'	NULL
:	NULL
GCT	NULL
GCA	NULL
CTT	NULL
GCA	NULL
GGA	NULL
GCG	NULL
CAC	NULL
;	NULL
probe	NULL
:	NULL
CAG	NULL
TAC	NULL
AGC	NULL
AAG	NULL
GTC	NULL
CTG	NULL
GCC	NULL
CTG	NULL
)	NULL
,	NULL
IFN-y	NULL
(	NULL
5	NULL
:	NULL
ACC	NULL
TTA	NULL
AGA	NULL
AAT	NULL
ATT	NULL
TTA	NULL
ATG	NULL
C	NULL
;	NULL
3	NULL
``	NULL
:	NULL
ACC	NULL
GAA	NULL
TAA	NULL
TTA	NULL
GTC	NULL
AGC	NULL
TT	NULL
;	NULL
probe	NULL
:	NULL
ATT	NULL
TGG	NULL
CTC	NULL
TGC	NULL
ATT	NULL
ATT	NULL
TTT	NULL
CTG	NULL
T	NULL
)	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
Ca	NULL
chain	NULL
(	NULL
5	NULL
'	NULL
:	NULL
GAA	NULL
CCC	NULL
TGA	NULL
CCC	NULL
TGC	NULL
CGT	NULL
GTA	NULL
CC	NULL
;	NULL
3	NULL
``	NULL
:	NULL
ATC	NULL
ATA	NULL
AAT	NULL
TCG	NULL
GGT	NULL
AGG	NULL
ATC	NULL
C	NULL
;	NULL
probe	NULL
:	NULL
AGC	NULL
AAC	NULL
AGT	NULL
GCT	NULL
GTG	NULL
GCC	NULL
TG	NULL
)	NULL
,	NULL
IxBa	NULL
(	NULL
5	NULL
'	NULL
:	NULL
GCT	NULL
GAA	NULL
GGA	NULL
GCG	NULL
GCT	NULL
AC	NULL
;	NULL
3	NULL
``	NULL
:	NULL
TCC	NULL
GGC	NULL
CAT	NULL
TAC	NULL
AGG	NULL
GCT	NULL
CC	NULL
;	NULL
probe	NULL
:	NULL
AGG	NULL
GAG	NULL
ACC	NULL
TG	NULL
G	NULL
CCT	NULL
TCC	NULL
TCA	NULL
A	NULL
)	NULL
.	NULL

Cytokine	NULL
semiquantification	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
using	NULL
a	NULL
commercial	NULL
kit	NULL
(	NULL
Trizol	NULL
;	NULL
Life	NULL
Technologies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

cDNA	NULL
of	NULL
all	NULL
samples	NULL
was	NULL
diluted	NULL
to	NULL
adjust	NULL
for	NULL
equal	NULL
B-actin	NULL
copy	NULL
numbers	NULL
.	NULL

Adjusted	NULL
cDNAs	NULL
were	NULL
amplified	NULL
by	NULL
PCR	NULL
using	NULL
the	NULL
cytokine-specific	NULL
primers	NULL
described	NULL
above	NULL
.	NULL

All	NULL
primers	NULL
were	NULL
human	NULL
species-specific	NULL
and	NULL
did	NULL
not	NULL
amplify	NULL
murine	NULL
sequences	NULL
.	NULL

Samples	NULL
from	NULL
treated	NULL
and	NULL
untreated	NULL
mice	NULL
were	NULL
always	NULL
run	NULL
in	NULL
parallel	NULL
.	NULL

PCR	NULL
conditions	NULL
consisted	NULL
of	NULL
denaturation	NULL
at	NULL
94°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
annealing	NULL
at	NULL
55°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
and	NULL
extension	NULL
for	NULL
2	NULL
min	NULL
at	NULL
72°C	NULL
for	NULL
30	NULL
cycles	NULL
with	NULL
a	NULL
final	NULL
10-min	NULL
extension	NULL
at	NULL
72°C	NULL
.	NULL

In	NULL
each	NULL
PCR	NULL
,	NULL
serial	NULL
dilutions	NULL
of	NULL
cytokine-specific	NULL
sequences	NULL
with	NULL
known	NULL
transcript	NULL
numbers	NULL
were	NULL
included	NULL
.	NULL

Amplified	NULL
products	NULL
were	NULL
blotted	NULL
and	NULL
hybridized	NULL
with	NULL
internal	NULL
probes	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
heat	NULL
denatured	NULL
at	NULL
94°C	NULL
for	NULL
5	NULL
min	NULL
,	NULL
blotted	NULL
onto	NULL
a	NULL
supported	NULL
nitrocellu-lose	NULL
membrane	NULL
(	NULL
Schleicher	NULL
and	NULL
Schuell	NULL
,	NULL
Keene	NULL
,	NULL
NH	NULL
)	NULL
,	NULL
and	NULL
baked	NULL
at	NULL
80°C	NULL
for	NULL
1	NULL
h	NULL
in	NULL
a	NULL
vacuum	NULL
oven	NULL
.	NULL

Membranes	NULL
were	NULL
transferred	NULL
into	NULL
pre-hybridization	NULL
solution	NULL
including	NULL
denatured	NULL
salmon	NULL
sperm	NULL
DNA	NULL
for	NULL
3	NULL
h	NULL
(	NULL
55°C	NULL
for	NULL
B-actin	NULL
,	NULL
IL-1B	NULL
and	NULL
IxBa	NULL
;	NULL
42°C	NULL
for	NULL
all	NULL
other	NULL
cytokines	NULL
)	NULL
.	NULL

After	NULL
prehybridization	NULL
,	NULL
cytokine-specific	NULL
biotinylated	NULL
probes	NULL
were	NULL
added	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
200	NULL
ng/ml	NULL
.	NULL

Hybridization	NULL
was	NULL
performed	NULL
overnight	NULL
at	NULL
the	NULL
same	NULL
temperature	NULL
as	NULL
prehybridization	NULL
.	NULL

Washing	NULL
was	NULL
performed	NULL
with	NULL
2x	NULL
SSC	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
for	NULL
10	NULL
min	NULL
at	NULL
42°C	NULL
and	NULL
for	NULL
5	NULL
min	NULL
at	NULL
55°C	NULL
.	NULL

The	NULL
last	NULL
wash	NULL
was	NULL
omitted	NULL
for	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
blots	NULL
.	NULL

Membranes	NULL
were	NULL
blocked	NULL
with	NULL
a	NULL
BSA-containing	NULL
solution	NULL
,	NULL
incubated	NULL
with	NULL
streptavidin-peroxidase	NULL
,	NULL
washed	NULL
twice	NULL
,	NULL
developed	NULL
with	NULL
nitro	NULL
blue	NULL
tetrazolium	NULL
chloride/bromo-chloro-indolyl-phosphate	NULL
,	NULL
and	NULL
scanned	NULL
(	NULL
AMBIS	NULL
system	NULL
;	NULL
Scanalytics	NULL
,	NULL
Billerica	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
serial	NULL
dilutions	NULL
of	NULL
cytokine	NULL
sequences	NULL
with	NULL
known	NULL
concentrations	NULL
were	NULL
processed	NULL
in	NULL
parallel	NULL
and	NULL
used	NULL
as	NULL
a	NULL
standard	NULL
curve	NULL
to	NULL
calculate	NULL
the	NULL
original	NULL
transcript	NULL
number	NULL
in	NULL
the	NULL
specimen	NULL
.	NULL

Results	NULL
Differential	NULL
sensitivity	NULL
of	NULL
T	NULL
cell	NULL
and	NULL
macrophage	NULL
products	NULL
to	NULL
in	NULL
vivo	NULL
glucocorticoid	NULL
treatment	NULL
.	NULL

Temporal	NULL
artery	NULL
specimens	NULL
from	NULL
GCA	NULL
patients	NULL
were	NULL
engrafted	NULL
in	NULL
SCID	NULL
mice	NULL
to	NULL
a	NULL
subcutaneous	NULL
transplant	NULL
site	NULL
.	NULL

In	NULL
these	NULL
xenografts	NULL
,	NULL
the	NULL
disease	NULL
process	NULL
continued	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
persistence	NULL
of	NULL
the	NULL
typical	NULL
histo-morphology	NULL
and	NULL
the	NULL
ongoing	NULL
transcription	NULL
of	NULL
T	NULL
cell-	NULL
and	NULL
macrophage-derived	NULL
cytokines	NULL
(	NULL
12	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
in	NULL
the	NULL
vascular	NULL
lesions	NULL
were	NULL
of	NULL
the	NULL
TH1	NULL
subtype	NULL
,	NULL
and	NULL
produced	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
.	NULL

IL-4	NULL
was	NULL
rarely	NULL
detected	NULL
in	NULL
the	NULL
tissue	NULL
.	NULL

Macrophage-derived	NULL
products	NULL
included	NULL
IL-1B	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
TGF-B1	NULL
.	NULL

Persistent	NULL
transcription	NULL
for	NULL
these	NULL
cytokines	NULL
was	NULL
followed	NULL
for	NULL
up	NULL
to	NULL
2	NULL
mo	NULL
in	NULL
the	NULL
xe-nografts	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
in	NULL
vivo	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
,	NULL
temporal	NULL
artery	NULL
specimens	NULL
from	NULL
patients	NULL
with	NULL
active	NULL
GCA	NULL
were	NULL
engrafted	NULL
subcutaneously	NULL
into	NULL
four	NULL
SCID	NULL
mice	NULL
,	NULL
and	NULL
treatment	NULL
was	NULL
initiated	NULL
3	NULL
wk	NULL
after	NULL
the	NULL
transplantation	NULL
.	NULL

The	NULL
mice	NULL
were	NULL
ei-	NULL
Glucocorticoids	NULL
in	NULL
Giant	NULL
Cell	NULL
Arteritis	NULL
2643	NULL
60,000	NULL
Ca	NULL
.	NULL

25,000	NULL
IL-Ip	NULL
20,000	NULL
40,000	NULL
15,000	NULL
10,000	NULL
20,000	NULL
5,000	NULL
3	NULL
0	NULL
0	NULL
g	NULL
3,000	NULL
IL-2	NULL
60,000	NULL
IL-6	NULL
Figure	NULL
1	NULL
.	NULL

Cytokine	NULL
transcripﬁon	NULL
in	NULL
.S	NULL
45.000	NULL
human	NULL
temporal	NULL
artery	NULL
specimens	NULL
3	NULL
2,000	NULL
'	NULL
retrieved	NULL
from	NULL
glucocorticoid-on	NULL
.	NULL

°	NULL
A	NULL
s	NULL
30,000	NULL
treated	NULL
human—mouse	NULL
chimeras	NULL
.	NULL

A	NULL
3	NULL
temporal	NULL
artery	NULL
specimen	NULL
from	NULL
a	NULL
é	NULL
1,000	NULL
15,000	NULL
GCA	NULL
patient	NULL
was	NULL
divided	NULL
into	NULL
four	NULL
.	NULL

$	NULL
segments	NULL
,	NULL
and	NULL
each	NULL
segment	NULL
was	NULL
g	NULL
0	NULL
0	NULL
implanted	NULL
into	NULL
a	NULL
NOD-SCID	NULL
<	NULL
15,000	NULL
16,000	NULL
mouse	NULL
.	NULL

3	NULL
wk	NULL
after	NULL
transplantatipn	NULL
,	NULL
é	NULL
IFN-y	NULL
TGF-BI	NULL
mice	NULL
were	NULL
treated	NULL
with	NULL
increasing	NULL
s	NULL
12,000	NULL
doses	NULL
of	NULL
dexamethasone	NULL
for	NULL
1	NULL
wk	NULL
.	NULL

10,000	NULL
T	NULL
Specimens	NULL
were	NULL
retrieved	NULL
and	NULL
ana-8,000	NULL
lyzed	NULL
for	NULL
the	NULL
in	NULL
situ	NULL
transcription	NULL
of	NULL
5.000	NULL
lymphokines	NULL
(	NULL
/eft	NULL
)	NULL
and	NULL
monokines	NULL
'	NULL
4,000	NULL
(	NULL
right	NULL
)	NULL
by	NULL
semiquantitative	NULL
PCR	NULL
and	NULL
hybridization	NULL
.	NULL

Results	NULL
are	NULL
0	NULL
0	NULL
shown	NULL
as	NULL
mean	NULL
of	NULL
three	NULL
experi-0	NULL
0.04	NULL
0.4	NULL
4	NULL
0	NULL
0.04	NULL
0.4	NULL
4	NULL
Dexamethasone	NULL
mg/kg	NULL
ther	NULL
sham-injected	NULL
or	NULL
received	NULL
dexamethasone	NULL
intraperitoneally	NULL
for	NULL
7	NULL
d	NULL
at	NULL
doses	NULL
of	NULL
0.04	NULL
,	NULL
0.4	NULL
,	NULL
and	NULL
4	NULL
mg/kg	NULL
,	NULL
respectively	NULL
.	NULL

Tissue	NULL
specimens	NULL
were	NULL
explanted	NULL
,	NULL
analyzed	NULL
by	NULL
immunohis-tochemistry	NULL
,	NULL
and	NULL
mRNA	NULL
cytokine	NULL
copy	NULL
numbers	NULL
were	NULL
semiquantified	NULL
by	NULL
PCR	NULL
amplification	NULL
and	NULL
dot-blotting	NULL
.	NULL

To	NULL
assure	NULL
comparability	NULL
of	NULL
tissue	NULL
quantity	NULL
,	NULL
B-actin	NULL
copy	NULL
numbers	NULL
were	NULL
determined	NULL
in	NULL
all	NULL
retrieved	NULL
specimens	NULL
,	NULL
and	NULL
cDNA	NULL
was	NULL
adjusted	NULL
to	NULL
achieve	NULL
equal	NULL
B-actin	NULL
copy	NULL
numbers	NULL
.	NULL

Results	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

As	NULL
demonstrated	NULL
by	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
for	NULL
the	NULL
TCR	NULL
«	NULL
chain	NULL
,	NULL
the	NULL
density	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
infiltrate	NULL
was	NULL
unaffected	NULL
by	NULL
steroid	NULL
treatment	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
grafts	NULL
exposed	NULL
to	NULL
4	NULL
mg/kg	NULL
dexamethasone	NULL
.	NULL

With	NULL
the	NULL
highest	NULL
dose	NULL
of	NULL
glucocorticoids	NULL
,	NULL
T	NULL
cell	NULL
numbers	NULL
in	NULL
the	NULL
inflammatory	NULL
lesions	NULL
decreased	NULL
by	NULL
30-35	NULL
%	NULL
.	NULL

Concentrations	NULL
of	NULL
IL-2-specific	NULL
transcripts	NULL
decreased	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
from	NULL
a	NULL
mean	NULL
of	NULL
2,370	NULL
copies	NULL
in	NULL
untreated	NULL
animals	NULL
to	NULL
a	NULL
mean	NULL
of	NULL
692	NULL
copies	NULL
in	NULL
the	NULL
highest	NULL
dose	NULL
group	NULL
.	NULL

The	NULL
suppressive	NULL
effect	NULL
of	NULL
steroids	NULL
was	NULL
less	NULL
pronounced	NULL
for	NULL
IFN-y-specific	NULL
sequences	NULL
.	NULL

Copy	NULL
numbers	NULL
of	NULL
IFN-y-specific	NULL
transcripts	NULL
were	NULL
unaltered	NULL
,	NULL
or	NULL
only	NULL
slightly	NULL
reduced	NULL
in	NULL
grafts	NULL
recovered	NULL
from	NULL
mice	NULL
treated	NULL
with	NULL
0.04	NULL
and	NULL
0.4	NULL
mg/kg	NULL
dexamethasone	NULL
.	NULL

Only	NULL
the	NULL
administration	NULL
of	NULL
4	NULL
mg/kg	NULL
dexamethasone	NULL
induced	NULL
a	NULL
marked	NULL
reduction	NULL
of	NULL
IFN-y	NULL
transcription	NULL
(	NULL
1,875	NULL
copies	NULL
vs.	NULL
5,816	NULL
copies	NULL
in	NULL
the	NULL
untreated	NULL
animal	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
administration	NULL
of	NULL
steroids	NULL
resulted	NULL
in	NULL
a	NULL
partial	NULL
inhibition	NULL
of	NULL
T	NULL
cell-derived	NULL
cytokines	NULL
.	NULL

The	NULL
inhibition	NULL
remained	NULL
incomplete	NULL
,	NULL
and	NULL
even	NULL
the	NULL
partial	NULL
inhibition	NULL
of	NULL
the	NULL
more	NULL
steroid-sensitive	NULL
IL-2	NULL
with	NULL
0.4	NULL
mg/kg	NULL
dexamethasone	NULL
required	NULL
five	NULL
times	NULL
higher	NULL
doses	NULL
than	NULL
those	NULL
usually	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
GCA	NULL
patients	NULL
.	NULL

Tissue-infiltrating	NULL
macrophages	NULL
have	NULL
been	NULL
found	NULL
to	NULL
fall	NULL
into	NULL
several	NULL
categories	NULL
according	NULL
to	NULL
the	NULL
spectrum	NULL
of	NULL
products	NULL
they	NULL
synthesize	NULL
in	NULL
situ	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
mediators	NULL
produced	NULL
correlates	NULL
with	NULL
a	NULL
strict	NULL
topographical	NULL
arrangement	NULL
.	NULL

Macro	NULL
28644	NULL
-	NULL
Brack	NULL
et	NULL
al	NULL
.	NULL

ments	NULL
using	NULL
temporal	NULL
artery	NULL
speci-	NULL
Dexamethasone	NULL
mg/kg	NULL
mens	NULL
from	NULL
three	NULL
patients	NULL
.	NULL

phages	NULL
expressing	NULL
IL-1B	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
TGF-B1	NULL
mRNA	NULL
have	NULL
been	NULL
mapped	NULL
to	NULL
the	NULL
tunica	NULL
adventitia	NULL
.	NULL

The	NULL
subset	NULL
of	NULL
macrophages	NULL
accumulating	NULL
in	NULL
the	NULL
intima	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
produce	NULL
iNOS	NULL
.	NULL

Macrophage-derived	NULL
products	NULL
were	NULL
sensitive	NULL
to	NULL
steroid-mediated	NULL
repression	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
TGF-B1	NULL
mRNA	NULL
.	NULL

Treatment	NULL
with	NULL
dexamethasone	NULL
was	NULL
followed	NULL
promptly	NULL
by	NULL
a	NULL
reduction	NULL
in	NULL
iNOS	NULL
.	NULL

Table	NULL
I	NULL
summarizes	NULL
the	NULL
result	NULL
of	NULL
immunohistochemical	NULL
analysis	NULL
with	NULL
iNOS-specific	NULL
antibodies	NULL
.	NULL

The	NULL
proportion	NULL
of	NULL
iNOS+	NULL
cells	NULL
declined	NULL
sharply	NULL
after	NULL
steroid	NULL
therapy	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
the	NULL
lowest	NULL
dose	NULL
of	NULL
dexamethasone	NULL
was	NULL
also	NULL
sufficient	NULL
to	NULL
affect	NULL
the	NULL
synthesis	NULL
of	NULL
IL-1B	NULL
mRNA	NULL
.	NULL

With	NULL
4	NULL
mg/kg	NULL
dexamethasone	NULL
,	NULL
IL-1	NULL
transcription	NULL
was	NULL
almost	NULL
completely	NULL
inhibited	NULL
.	NULL

IL-1	NULL
transcripts	NULL
were	NULL
downregulated	NULL
from	NULL
a	NULL
mean	NULL
of	NULL
16,839	NULL
copies	NULL
in	NULL
untreated	NULL
tissues	NULL
to	NULL
a	NULL
mean	NULL
of	NULL
1,186	NULL
transcripts	NULL
in	NULL
the	NULL
highest	NULL
steroid	NULL
dosage	NULL
group	NULL
.	NULL

Steroid	NULL
effects	NULL
were	NULL
less	NULL
apparent	NULL
for	NULL
IL-6	NULL
,	NULL
which	NULL
was	NULL
rather	NULL
resistant	NULL
to	NULL
0.4	NULL
Table	NULL
I.	NULL
iNOS	NULL
Expression	NULL
in	NULL
Temporal	NULL
Artery	NULL
Tissues	NULL
Retrieved	NULL
from	NULL
Glucocorticoid-treated	NULL
GCA-SCID	NULL
Mouse	NULL
Chimeras	NULL
Tissue	NULL
specimen	NULL
Dexamethasone	NULL
iNOS-expressing	NULL
cells	NULL
mg/kg	NULL
cells/mm	NULL
Patient	NULL
1	NULL
0	NULL
92	NULL
0.04	NULL
11	NULL
0.4	NULL
10	NULL
4	NULL
21	NULL
Patient	NULL
2	NULL
0	NULL
34	NULL
0.04	NULL
25	NULL
0.4	NULL
22	NULL
4	NULL
5	NULL
Figure	NULL
2	NULL
.	NULL

TGF-B1	NULL
production	NULL
in	NULL
temporal	NULL
artery	NULL
specimens	NULL
retrieved	NULL
from	NULL
glucocorticoid-treated	NULL
human	NULL
tissue-SCID	NULL
mouse	NULL
chimera	NULL
.	NULL

Temporal	NULL
artery	NULL
tissue	NULL
retrieved	NULL
from	NULL
an	NULL
untreated	NULL
mouse	NULL
(	NULL
top	NULL
)	NULL
and	NULL
a	NULL
mouse	NULL
treated	NULL
with	NULL
0.4	NULL
mg/kg	NULL
dexamethasone	NULL
for	NULL
1	NULL
wk	NULL
(	NULL
bottom	NULL
)	NULL
were	NULL
stained	NULL
with	NULL
anti-TGF-B1	NULL
antibodies	NULL
.	NULL

Production	NULL
of	NULL
TGF-B1	NULL
in	NULL
the	NULL
inflammatory	NULL
infiltrate	NULL
was	NULL
not	NULL
suppressed	NULL
by	NULL
glucocorticoids	NULL
.	NULL

Immunofluorescence	NULL
,	NULL
X400	NULL
.	NULL

mg/kg	NULL
dexamethasone	NULL
.	NULL

With	NULL
higher	NULL
doses	NULL
,	NULL
IL-6	NULL
mRNA	NULL
copy	NULL
numbers	NULL
were	NULL
reduced	NULL
from	NULL
25,626	NULL
to	NULL
9,437	NULL
.	NULL

Among	NULL
all	NULL
the	NULL
cytokines	NULL
analyzed	NULL
,	NULL
TGF-B1	NULL
had	NULL
a	NULL
unique	NULL
position	NULL
.	NULL

TGF-B1	NULL
mRNA	NULL
production	NULL
was	NULL
unaffected	NULL
by	NULL
the	NULL
treatment	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
cytokine	NULL
is	NULL
steroid	NULL
resistant	NULL
.	NULL

Even	NULL
in	NULL
the	NULL
tissues	NULL
harvested	NULL
from	NULL
mice	NULL
injected	NULL
with	NULL
a	NULL
7-d	NULL
course	NULL
of	NULL
4	NULL
mg/kg	NULL
dexamethasone	NULL
,	NULL
TGF-B1	NULL
transcription	NULL
persisted	NULL
with	NULL
a	NULL
mean	NULL
copy	NULL
number	NULL
of	NULL
7,620	NULL
as	NULL
compared	NULL
to	NULL
9,535	NULL
copies	NULL
in	NULL
sham-treated	NULL
animals	NULL
.	NULL

The	NULL
persistence	NULL
of	NULL
TGF-B1	NULL
production	NULL
in	NULL
glucocorticoid-treated	NULL
animals	NULL
was	NULL
confirmed	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
shows	NULL
temporal	NULL
artery	NULL
tissues	NULL
retrieved	NULL
from	NULL
an	NULL
untreated	NULL
and	NULL
a	NULL
treated	NULL
mouse	NULL
stained	NULL
with	NULL
an	NULL
anti-TGF-B1	NULL
antibody	NULL
.	NULL

There	NULL
was	NULL
no	NULL
decline	NULL
in	NULL
the	NULL
number	NULL
of	NULL
TGF-B1-producing	NULL
cells	NULL
after	NULL
glucocorticoid	NULL
treatment	NULL
.	NULL

In	NULL
vivo	NULL
steroid-mediated	NULL
regulation	NULL
of	NULL
NFkB	NULL
.	NULL

The	NULL
antiinflammatory	NULL
action	NULL
of	NULL
steroids	NULL
has	NULL
been	NULL
attributed	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
the	NULL
transrepression	NULL
of	NULL
cytokine	NULL
mRNA	NULL
.	NULL

Mechanisms	NULL
underlying	NULL
the	NULL
cytokine	NULL
suppressive	NULL
effects	NULL
in	NULL
vitro	NULL
are	NULL
beginning	NULL
to	NULL
be	NULL
understood	NULL
.	NULL

Steroids	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
IxBa	NULL
transcription	NULL
,	NULL
and	NULL
thereby	NULL
to	NULL
reduce	NULL
the	NULL
availability	NULL
of	NULL
nuclear	NULL
NFB	NULL
leading	NULL
to	NULL
a	NULL
decreased	NULL
expression	NULL
of	NULL
IL-2	NULL
.	NULL

To	NULL
in	NULL
8,000	NULL
Patient	NULL
1	NULL
6,000	NULL
4,000	NULL
2,000	NULL
6,000	NULL
Patient	NULL
2	NULL
4,000	NULL
}	NULL
2,000	NULL
|	NULL
4,000	NULL
Patient	NULL
3	NULL
3,000	NULL
IkxBa	NULL
mRNA	NULL
copy	NULL
numbers/200,000	NULL
f-actin	NULL
copies	NULL
2,000	NULL
|	NULL
1,000	NULL
\	NULL
T	NULL
0	NULL
0.04	NULL
0.4	NULL
Dexamethasone	NULL
(	NULL
mg/kg	NULL
)	NULL
Figure	NULL
3	NULL
.	NULL

Induction	NULL
of	NULL
IxBa	NULL
transcription	NULL
by	NULL
dexamethasone	NULL
in	NULL
human	NULL
GCA	NULL
tissue	NULL
.	NULL

Mouse	NULL
chimeras	NULL
were	NULL
generated	NULL
and	NULL
treated	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Tissue	NULL
was	NULL
retrieved	NULL
and	NULL
the	NULL
number	NULL
of	NULL
IxBa	NULL
sequences	NULL
in	NULL
the	NULL
tissue	NULL
was	NULL
determined	NULL
by	NULL
semiquantitative	NULL
PCR	NULL
.	NULL

Results	NULL
for	NULL
three	NULL
different	NULL
patients	NULL
are	NULL
shown	NULL
.	NULL

vestigate	NULL
whether	NULL
this	NULL
mechanism	NULL
is	NULL
functional	NULL
in	NULL
vivo	NULL
,	NULL
IkxBa	NULL
mRNA	NULL
transcripts	NULL
were	NULL
measured	NULL
in	NULL
temporal	NULL
artery	NULL
grafts	NULL
from	NULL
three	NULL
distinct	NULL
patients	NULL
.	NULL

Mice	NULL
were	NULL
either	NULL
sham-treated	NULL
or	NULL
treated	NULL
with	NULL
daily	NULL
injections	NULL
of	NULL
0.04	NULL
and	NULL
0.4	NULL
mg/kg	NULL
dexamethasone	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
1	NULL
wk	NULL
.	NULL

Results	NULL
from	NULL
the	NULL
retrieved	NULL
tissue	NULL
specimens	NULL
are	NULL
given	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

In	NULL
all	NULL
three	NULL
experiments	NULL
administration	NULL
of	NULL
glucocorticoids	NULL
led	NULL
to	NULL
a	NULL
doubling	NULL
in	NULL
the	NULL
concentration	NULL
of	NULL
IxBa	NULL
mRNA	NULL
.	NULL

IxBa	NULL
induction	NULL
in	NULL
the	NULL
tissue	NULL
was	NULL
already	NULL
achieved	NULL
with	NULL
the	NULL
lower	NULL
dexamethasone	NULL
doses	NULL
.	NULL

In	NULL
one	NULL
patient	NULL
,	NULL
0.04	NULL
mg/kg	NULL
dexamethasone	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
a	NULL
maximal	NULL
response	NULL
.	NULL

Steroid-mediated	NULL
induction	NULL
of	NULL
IxBa	NULL
traps	NULL
NFxb	NULL
in	NULL
the	NULL
cy-toplasm	NULL
,	NULL
and	NULL
thus	NULL
causes	NULL
transrepression	NULL
of	NULL
steroid-sensitive	NULL
cytokine	NULL
genes	NULL
.	NULL

Functional	NULL
NFB	NULL
sites	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
have	NULL
been	NULL
identified	NULL
for	NULL
IL-2	NULL
,	NULL
IL-1B	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
iNOS	NULL
,	NULL
but	NULL
are	NULL
lacking	NULL
in	NULL
IFN-y	NULL
and	NULL
TGF-B1	NULL
.	NULL

Interference	NULL
with	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFkB	NULL
would	NULL
thus	NULL
provide	NULL
an	NULL
excellent	NULL
explanation	NULL
for	NULL
the	NULL
differential	NULL
modulation	NULL
of	NULL
cytokines	NULL
demonstrated	NULL
in	NULL
the	NULL
GCA	NULL
tissue	NULL
.	NULL

To	NULL
further	NULL
explore	NULL
whether	NULL
in	NULL
vivo	NULL
glucocorticoid	NULL
therapy	NULL
is	NULL
associated	NULL
with	NULL
downregulation	NULL
of	NULL
free	NULL
nuclear	NULL
NFkb	NULL
,	NULL
the	NULL
nuclear	NULL
expression	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
was	NULL
compared	NULL
in	NULL
tissue	NULL
sections	NULL
from	NULL
untreated	NULL
and	NULL
treated	NULL
xenotransplants	NULL
.	NULL

Free	NULL
nuclear	NULL
NFkB	NULL
was	NULL
immunohistochemically	NULL
detected	NULL
through	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
the	NULL
NLS	NULL
of	NULL
Glucocorticoids	NULL
in	NULL
Giant	NULL
Cell	NULL
Arteritis	NULL
2645	NULL
wf	NULL
/*	NULL
w	NULL
x	NULL
Tze	NULL
,	NULL
Figure	NULL
4	NULL
.	NULL

Dexamethasone	NULL
reduces	NULL
the	NULL
availability	NULL
of	NULL
free	NULL
nuclear	NULL
NFxB	NULL
in	NULL
the	NULL
inflammatory	NULL
infiltrate	NULL
of	NULL
human	NULL
GCA-mouse	NULL
chimeras	NULL
.	NULL

NOD-SCID	NULL
mice	NULL
were	NULL
engrafted	NULL
with	NULL
temporal	NULL
artery	NULL
tissue	NULL
and	NULL
treated	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Adjacent	NULL
sections	NULL
were	NULL
stained	NULL
with	NULL
either	NULL
anti-CD3	NULL
to	NULL
document	NULL
the	NULL
T	NULL
cell	NULL
infiltrate	NULL
(	NULL
top	NULL
)	NULL
or	NULL
an	NULL
antibody	NULL
to	NULL
the	NULL
NLS	NULL
of	NULL
human	NULL
ReL-A	NULL
(	NULL
bottom	NULL
)	NULL
which	NULL
only	NULL
recognizes	NULL
free	NULL
nuclear	NULL
NFxB	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Tissue	NULL
sections	NULL
from	NULL
untreated	NULL
mice	NULL
(	NULL
/eff	NULL
)	NULL
and	NULL
from	NULL
mice	NULL
treated	NULL
with	NULL
0.4	NULL
mg/kg	NULL
dexamethasone	NULL
(	NULL
right	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

Nuclear	NULL
expression	NULL
of	NULL
NFxB	NULL
de-	NULL
clined	NULL
with	NULL
glucocorticoid	NULL
treatment	NULL
.	NULL

X400	NULL
.	NULL

the	NULL
p65	NULL
component	NULL
of	NULL
NFx	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
NLS	NULL
epitope	NULL
becomes	NULL
accessible	NULL
to	NULL
the	NULL
antibody	NULL
when	NULL
the	NULL
p50/p65	NULL
heterodimer	NULL
dissociates	NULL
from	NULL
IxBa	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
immunohistochemical	NULL
approach	NULL
specifically	NULL
stains	NULL
transcriptionally	NULL
active	NULL
NFkB	NULL
.	NULL

Temporal	NULL
artery	NULL
segments	NULL
from	NULL
two	NULL
different	NULL
patients	NULL
were	NULL
engrafted	NULL
,	NULL
and	NULL
the	NULL
mice	NULL
were	NULL
either	NULL
sham-injected	NULL
,	NULL
or	NULL
received	NULL
0.04	NULL
,	NULL
0.4	NULL
,	NULL
and	NULL
4	NULL
mg/kg	NULL
dexamethasone	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
seven	NULL
consecutive	NULL
days	NULL
.	NULL

Grafts	NULL
were	NULL
harvested	NULL
,	NULL
sectioned	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
rabbit	NULL
anti-human	NULL
CD3	NULL
to	NULL
identify	NULL
tissue-infiltrating	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Adjacent	NULL
sections	NULL
were	NULL
stained	NULL
with	NULL
the	NULL
mAb	NULL
specific	NULL
for	NULL
free	NULL
nuclear	NULL
NFkB	NULL
.	NULL

NFkB+	NULL
cells	NULL
were	NULL
markedly	NULL
reduced	NULL
,	NULL
indicating	NULL
that	NULL
steroid	NULL
injections	NULL
lead	NULL
to	NULL
the	NULL
trapping	NULL
of	NULL
NFkB	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

In	NULL
tissues	NULL
retrieved	NULL
from	NULL
mice	NULL
treated	NULL
with	NULL
0.04	NULL
mg/	NULL
kg	NULL
,	NULL
free	NULL
nuclear	NULL
NFB	NULL
was	NULL
reduced	NULL
but	NULL
still	NULL
present	NULL
.	NULL

High	NULL
doses	NULL
of	NULL
dexamethasone	NULL
essentially	NULL
led	NULL
to	NULL
the	NULL
disappearance	NULL
of	NULL
nuclear	NULL
NFkB	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
IxBa	NULL
for	NULL
NFB	NULL
can	NULL
be	NULL
potentiated	NULL
by	NULL
APDTC	NULL
.	NULL

Dithiocarbamates	NULL
reversibly	NULL
suppress	NULL
the	NULL
dissociation	NULL
of	NULL
IxBa	NULL
from	NULL
the	NULL
latent	NULL
cytoplasmic	NULL
form	NULL
of	NULL
NFkB	NULL
(	NULL
14	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
dithiocarbamates	NULL
induce	NULL
a	NULL
similar	NULL
pattern	NULL
of	NULL
cytokine	NULL
repression	NULL
as	NULL
glucocorticoids	NULL
,	NULL
SCID	NULL
mice	NULL
engrafted	NULL
with	NULL
temporal	NULL
arteries	NULL
from	NULL
GCA	NULL
patients	NULL
were	NULL
treated	NULL
with	NULL
APDTC	NULL
for	NULL
24	NULL
h.	NULL
IL-6	NULL
and	NULL
TGF-B1	NULL
mRNA	NULL
was	NULL
semiquantified	NULL
in	NULL
tissue	NULL
extracts	NULL
to	NULL
examine	NULL
whether	NULL
the	NULL
suppression	NULL
of	NULL
IL-6	NULL
and	NULL
the	NULL
sparing	NULL
of	NULL
TGF-B1	NULL
transcription	NULL
can	NULL
be	NULL
mimicked	NULL
28646	NULL
-	NULL
Brack	NULL
et	NULL
al	NULL
.	NULL

by	NULL
NFkB	NULL
inhibition	NULL
.	NULL

Administration	NULL
of	NULL
dithiocarbamate	NULL
to	NULL
SCID	NULL
mice	NULL
carrying	NULL
xenotransplants	NULL
resulted	NULL
in	NULL
downregulation	NULL
of	NULL
IL-6	NULL
mRNA	NULL
synthesis	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
already	NULL
seen	NULL
with	NULL
the	NULL
treatment	NULL
regimen	NULL
using	NULL
a	NULL
low	NULL
dose	NULL
of	NULL
APDTC	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
TGF-B1	NULL
was	NULL
completely	NULL
unaffected	NULL
,	NULL
even	NULL
with	NULL
the	NULL
highest	NULL
dose	NULL
in	NULL
two	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
recently	NULL
that	NULL
IL-6-producing	NULL
macrophages	NULL
always	NULL
cosynthe-size	NULL
TGF-B1	NULL
,	NULL
excluding	NULL
a	NULL
nonspecific	NULL
toxic	NULL
effect	NULL
of	NULL
APDTC	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
differential	NULL
modulation	NULL
of	NULL
the	NULL
two	NULL
macrophage-derived	NULL
products	NULL
lends	NULL
further	NULL
support	NULL
to	NULL
the	NULL
model	NULL
that	NULL
steroids	NULL
affect	NULL
the	NULL
inflammatory	NULL
lesions	NULL
via	NULL
NFB	NULL
specific	NULL
inhibition	NULL
.	NULL

Persistence	NULL
of	NULL
TGF-BI-producing	NULL
macrophages	NULL
despite	NULL
successful	NULL
suppression	NULL
of	NULL
T	NULL
cell	NULL
function	NULL
in	NULL
chronically	NULL
treated	NULL
GCA	NULL
.	NULL

Experiments	NULL
in	NULL
the	NULL
steroid-treated	NULL
GCA-SCID	NULL
chimeras	NULL
are	NULL
best	NULL
compatible	NULL
with	NULL
transrepression	NULL
of	NULL
NFkB-sensitive	NULL
cytokines	NULL
,	NULL
which	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
prompt	NULL
improvement	NULL
of	NULL
clinical	NULL
symptoms	NULL
in	NULL
steroid-treated	NULL
patients	NULL
.	NULL

Never-theless	NULL
,	NULL
patients	NULL
need	NULL
to	NULL
be	NULL
maintained	NULL
on	NULL
steroids	NULL
,	NULL
and	NULL
they	NULL
tend	NULL
to	NULL
relapse	NULL
if	NULL
steroids	NULL
are	NULL
discontinued	NULL
within	NULL
the	NULL
first	NULL
years	NULL
of	NULL
treatment	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
the	NULL
dynamics	NULL
of	NULL
the	NULL
inflammatory	NULL
infiltrate	NULL
under	NULL
steroid	NULL
treatment	NULL
allows	NULL
conclusions	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
chronicity	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
chronic	NULL
steroid	NULL
administration	NULL
on	NULL
GCA-SCID	NULL
chimeras	NULL
.	NULL

Fragments	NULL
of	NULL
temporal	NULL
artery	NULL
specimens	NULL
were	NULL
implanted	NULL
into	NULL
SCID	NULL
mice	NULL
,	NULL
and	NULL
the	NULL
mice	NULL
were	NULL
either	NULL
treated	NULL
_	NULL
TGF-BI	NULL
<	NULL
100	NULL
B	NULL
i=	NULL
]	NULL
0	NULL
&	NULL
&	NULL
80	NULL
F	NULL
3	NULL
IL-6	NULL
.9	NULL
ts	NULL
5	NULL
60	NULL
|-6	NULL
o	NULL
8	NULL
40	NULL
|	NULL
sh	NULL
©	NULL
.€	NULL
€	NULL
€	NULL
,	NULL
20	NULL
O	NULL
0	NULL
control	NULL
375	NULL
3750	NULL
Ammonium	NULL
Pyrrolidine	NULL
Dithiocarbamate	NULL
(	NULL
uM	NULL
)	NULL
Figure	NULL
5	NULL
.	NULL

Treatment	NULL
with	NULL
dithiocarbamate	NULL
suppresses	NULL
in	NULL
situ	NULL
production	NULL
of	NULL
IL-6	NULL
,	NULL
but	NULL
not	NULL
of	NULL
TGF-B1	NULL
,	NULL
in	NULL
human	NULL
GCA-mouse	NULL
chimeras	NULL
.	NULL

Human-mouse	NULL
chimeras	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
buffer	NULL
control	NULL
only	NULL
or	NULL
a	NULL
total	NULL
dose	NULL
of	NULL
375	NULL
and	NULL
3,750	NULL
M	NULL
APDTC	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
situ	NULL
transcription	NULL
of	NULL
IL-6	NULL
and	NULL
TGF-B1	NULL
mRNA	NULL
was	NULL
semiquantified	NULL
by	NULL
PCR	NULL
and	NULL
hybridization	NULL
.	NULL

Results	NULL
from	NULL
one	NULL
out	NULL
of	NULL
three	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

with	NULL
daily	NULL
injections	NULL
of	NULL
sterile	NULL
PBS	NULL
,	NULL
or	NULL
with	NULL
0.4	NULL
mg/kg	NULL
dexamethasone	NULL
for	NULL
28	NULL
d.	NULL
Prolonged	NULL
glucocorticoid	NULL
therapy	NULL
did	NULL
not	NULL
dramatically	NULL
change	NULL
the	NULL
histology	NULL
of	NULL
the	NULL
inflammatory	NULL
lesion	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
demonstrates	NULL
that	NULL
an	NULL
inflammatory	NULL
infiltrate	NULL
composed	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
macrophages	NULL
persists	NULL
in	NULL
the	NULL
treated	NULL
as	NULL
well	NULL
as	NULL
untreated	NULL
animals	NULL
.	NULL

Cytokine	NULL
transcription	NULL
in	NULL
the	NULL
retrieved	NULL
tissues	NULL
was	NULL
semiquantified	NULL
as	NULL
described	NULL
above	NULL
.	NULL

A	NULL
summary	NULL
of	NULL
the	NULL
results	NULL
from	NULL
three	NULL
experiments	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
the	NULL
persisting	NULL
T	NULL
cell	NULL
infiltrate	NULL
,	NULL
the	NULL
transcription	NULL
of	NULL
TCR	NULL
«	NULL
chain	NULL
sequences	NULL
in	NULL
treated	NULL
mice	NULL
was	NULL
minimal	NULL
with	NULL
a	NULL
significant	NULL
reduction	NULL
compared	NULL
to	NULL
untreated	NULL
tissue	NULL
(	NULL
P	NULL
=	NULL
0.017	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
production	NULL
of	NULL
IFN-y	NULL
transcripts	NULL
essentially	NULL
ceased	NULL
(	NULL
P	NULL
=	NULL
0.047	NULL
)	NULL
.	NULL

4	NULL
wk	NULL
of	NULL
continuous	NULL
treatment	NULL
was	NULL
thus	NULL
able	NULL
to	NULL
abrogate	NULL
T	NULL
cell	NULL
function	NULL
in	NULL
the	NULL
vascular	NULL
lesions	NULL
,	NULL
including	NULL
the	NULL
NFkB-independent	NULL
production	NULL
of	NULL
IFN-y	NULL
.	NULL

A	NULL
different	NULL
picture	NULL
emerged	NULL
for	NULL
the	NULL
functional	NULL
activities	NULL
of	NULL
macrophages	NULL
.	NULL

The	NULL
antiinflammatory	NULL
action	NULL
of	NULL
chronic	NULL
steroid	NULL
administration	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
marked	NULL
suppression	NULL
of	NULL
IL-1B	NULL
transcription	NULL
(	NULL
P	NULL
=	NULL
0.028	NULL
)	NULL
.	NULL

Synthesis	NULL
of	NULL
IL-6	NULL
mRNA	NULL
was	NULL
significantly	NULL
reduced	NULL
(	NULL
P	NULL
=	NULL
0.028	NULL
)	NULL
but	NULL
persisted	NULL
at	NULL
low	NULL
levels	NULL
.	NULL

Median	NULL
copy	NULL
numbers	NULL
of	NULL
IL-6	NULL
mRNA	NULL
were	NULL
estimated	NULL
at	NULL
10,753	NULL
in	NULL
the	NULL
untreated	NULL
tissue	NULL
samples	NULL
versus	NULL
3,650	NULL
in	NULL
the	NULL
treated	NULL
specimens	NULL
.	NULL

No	NULL
therapeutic	NULL
effect	NULL
from	NULL
glucocorticoids	NULL
was	NULL
found	NULL
for	NULL
TGF-B1	NULL
mRNA	NULL
.	NULL

Even	NULL
a	NULL
course	NULL
of	NULL
4	NULL
wk	NULL
of	NULL
glucocorticoids	NULL
could	NULL
not	NULL
diminish	NULL
the	NULL
production	NULL
of	NULL
TGF-B1	NULL
mRNA	NULL
.	NULL

There	NULL
was	NULL
even	NULL
a	NULL
trend	NULL
for	NULL
higher	NULL
concentrations	NULL
of	NULL
TGF-B1	NULL
mRNA	NULL
in	NULL
the	NULL
explants	NULL
exposed	NULL
to	NULL
4	NULL
wk	NULL
of	NULL
continuous	NULL
steroids	NULL
when	NULL
compared	NULL
to	NULL
untreated	NULL
temporal	NULL
artery	NULL
fragments	NULL
,	NULL
however	NULL
,	NULL
this	NULL
trend	NULL
was	NULL
not	NULL
significant	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
macrophages	NULL
persist	NULL
in	NULL
spite	NULL
of	NULL
steroid	NULL
treatment	NULL
in	NULL
the	NULL
arterial	NULL
tissue	NULL
,	NULL
and	NULL
continue	NULL
to	NULL
be	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
T	NULL
cell-derived	NULL
lymphokine	NULL
production	NULL
as	NULL
documented	NULL
by	NULL
the	NULL
in	NULL
situ	NULL
synthesis	NULL
of	NULL
TGF-B1	NULL
.	NULL

Figure	NULL
6	NULL
.	NULL

Persistence	NULL
of	NULL
the	NULL
inflammatory	NULL
infiltrate	NULL
in	NULL
chronically	NULL
treated	NULL
GCA-mouse	NULL
chimera	NULL
.	NULL

NOD-SCID	NULL
mice	NULL
implanted	NULL
with	NULL
temporal	NULL
artery	NULL
specimens	NULL
were	NULL
either	NULL
sham-treated	NULL
or	NULL
treated	NULL
with	NULL
dexamethasone	NULL
,	NULL
0.4	NULL
mg/kg	NULL
,	NULL
for	NULL
28	NULL
d.	NULL
Immunohistochemistry	NULL
with	NULL
anti-CD3	NULL
(	NULL
top	NULL
)	NULL
and	NULL
anti-CD68	NULL
antibodies	NULL
(	NULL
bottom	NULL
)	NULL
in	NULL
untreated	NULL
(	NULL
/eft	NULL
)	NULL
and	NULL
treated	NULL
mice	NULL
(	NULL
right	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

Infiltration	NULL
with	NULL
T	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
macrophages	NULL
persisted	NULL
.	NULL

X100	NULL
.	NULL

Glucocorticoids	NULL
in	NULL
Giant	NULL
Cell	NULL
Arteritis	NULL
2647	NULL
IL-1	NULL
B	NULL
IL-6	NULL
TGF-B1	NULL
20000	NULL
p	NULL
=0.028	NULL
p	NULL
=	NULL
0.028	NULL
p=n.s	NULL
a	NULL
o	NULL
'	NULL
6-9	NULL
-	NULL
15000	NULL
-S	NULL
3	NULL
ch	NULL
.	NULL

s	NULL
3	NULL
10000	NULL
=	NULL
&	NULL
C	NULL
!	NULL

a	NULL
.2	NULL
&	NULL
o	NULL
5000	NULL
3	NULL
E	NULL
a	NULL
0	NULL
t	NULL
t	NULL
.	NULL

r	NULL
r	NULL
i	NULL
control	NULL
|	NULL
steroids	NULL
control	NULL
.	NULL

steroids	NULL
control	NULL
.	NULL

steroids	NULL
Ca	NULL
.	NULL

IFN-y	NULL
25000	NULL
10000	NULL
p	NULL
=	NULL
0.017	NULL
p	NULL
=	NULL
0.047	NULL
§	NULL
20000	NULL
8000	NULL
5	NULL
.	NULL

8	NULL
5	NULL
8	NULL
15000	NULL
4	NULL
6000	NULL
co.	NULL
3	NULL
<	NULL
S	NULL
a	NULL
10000	NULL
4	NULL
4000	NULL
8	NULL
'	NULL
C	NULL
.	NULL

8	NULL
<	NULL
5000	NULL
2000	NULL
4	NULL
2	NULL
eL	NULL
£	NULL
0	NULL
u	NULL
t	NULL
u	NULL
f	NULL
control	NULL
steroids	NULL
control	NULL
steroids	NULL
Figure	NULL
7	NULL
.	NULL

Persistent	NULL
TGF-B1	NULL
production	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
chronically	NULL
treated	NULL
GCA-mouse	NULL
chimeras	NULL
.	NULL

Human	NULL
tissue-SCID	NULL
mouse	NULL
chimeras	NULL
were	NULL
treated	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

In	NULL
situ	NULL
cytokine	NULL
transcription	NULL
in	NULL
retrieved	NULL
tissues	NULL
was	NULL
determined	NULL
by	NULL
semiquantitative	NULL
PCR	NULL
.	NULL

Results	NULL
from	NULL
three	NULL
experiments	NULL
using	NULL
five	NULL
untreated	NULL
and	NULL
six	NULL
treated	NULL
mice	NULL
are	NULL
shown	NULL
as	NULL
box	NULL
graphs	NULL
displaying	NULL
medians	NULL
,	NULL
25th	NULL
and	NULL
75th	NULL
percentiles	NULL
,	NULL
and	NULL
10th	NULL
and	NULL
90th	NULL
percentiles	NULL
,	NULL
as	NULL
whiskers	NULL
.	NULL

Discussion	NULL
Glucocorticoid	NULL
responsiveness	NULL
is	NULL
a	NULL
common	NULL
denominator	NULL
of	NULL
most	NULL
human	NULL
autoimmune	NULL
diseases	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Therapeutic	NULL
benefits	NULL
from	NULL
steroid	NULL
therapy	NULL
have	NULL
indeed	NULL
been	NULL
cited	NULL
as	NULL
evidence	NULL
for	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
to	NULL
chronic	NULL
inflammatory	NULL
diseases	NULL
,	NULL
and	NULL
glucocorticoids	NULL
are	NULL
considered	NULL
quintessential	NULL
immunosuppressants	NULL
.	NULL

Although	NULL
in	NULL
vitro	NULL
molecular	NULL
studies	NULL
have	NULL
provided	NULL
information	NULL
on	NULL
the	NULL
cellular	NULL
pathways	NULL
,	NULL
very	NULL
little	NULL
is	NULL
known	NULL
on	NULL
the	NULL
action	NULL
of	NULL
chronic	NULL
steroid	NULL
therapy	NULL
in	NULL
vivo	NULL
in	NULL
human	NULL
diseases	NULL
.	NULL

Initially	NULL
,	NULL
glucocorticoids	NULL
were	NULL
shown	NULL
to	NULL
suppress	NULL
the	NULL
AP-1	NULL
(	NULL
c-jun/c-fos	NULL
)	NULL
transcription	NULL
factor	NULL
(	NULL
6-9	NULL
)	NULL
.	NULL

More	NULL
re-cently	NULL
,	NULL
evidence	NULL
has	NULL
been	NULL
provided	NULL
that	NULL
glucocorticoids	NULL
function	NULL
by	NULL
blocking	NULL
the	NULL
nuclear	NULL
translocation	NULL
and	NULL
DNA	NULL
binding	NULL
of	NULL
NFB	NULL
through	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
IxBa	NULL
protein	NULL
and	NULL
cytoplasmic	NULL
trapping	NULL
of	NULL
NFkB	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

NFB	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
inducible	NULL
regulation	NULL
of	NULL
a	NULL
large	NULL
spectrum	NULL
of	NULL
genes	NULL
,	NULL
several	NULL
of	NULL
which	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
function	NULL
of	NULL
immune	NULL
cells	NULL
and	NULL
encode	NULL
for	NULL
inflammatory	NULL
mediators	NULL
(	NULL
16	NULL
)	NULL
.	NULL

How	NULL
transrepression	NULL
of	NULL
cytokines	NULL
changes	NULL
the	NULL
interaction	NULL
of	NULL
cells	NULL
accumulated	NULL
in	NULL
chronic	NULL
inflammatory	NULL
lesions	NULL
has	NULL
not	NULL
been	NULL
studied	NULL
.	NULL

Here	NULL
we	NULL
are	NULL
presenting	NULL
data	NULL
on	NULL
steroid-mediated	NULL
effects	NULL
in	NULL
vivo	NULL
induced	NULL
with	NULL
short-	NULL
as	NULL
well	NULL
as	NULL
long-term	NULL
treatment	NULL
in	NULL
a	NULL
human	NULL
inflammatory	NULL
disease	NULL
.	NULL

28648	NULL
-	NULL
Brack	NULL
et	NULL
al	NULL
.	NULL

These	NULL
studies	NULL
were	NULL
facilitated	NULL
by	NULL
the	NULL
availability	NULL
of	NULL
a	NULL
human	NULL
tissue-SCID	NULL
mouse	NULL
chimera	NULL
model	NULL
in	NULL
which	NULL
the	NULL
inflammation	NULL
characteristic	NULL
for	NULL
patients	NULL
with	NULL
GCA	NULL
was	NULL
self-sustained	NULL
and	NULL
persisted	NULL
for	NULL
at	NULL
least	NULL
2	NULL
mo	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
short-term	NULL
effects	NULL
of	NULL
steroid	NULL
treatment	NULL
were	NULL
characterized	NULL
by	NULL
a	NULL
differential	NULL
modulation	NULL
of	NULL
cytokines	NULL
in	NULL
the	NULL
infiltrate	NULL
which	NULL
correlated	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
IxBa	NULL
and	NULL
the	NULL
reduced	NULL
availability	NULL
of	NULL
free	NULL
nuclear	NULL
NFkB	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
these	NULL
pharmacological	NULL
effects	NULL
,	NULL
the	NULL
long-term	NULL
treatment	NULL
allowed	NULL
conclusions	NULL
on	NULL
the	NULL
biology	NULL
of	NULL
the	NULL
infiltrate	NULL
under	NULL
immunosuppression	NULL
.	NULL

The	NULL
continuous	NULL
immunosuppressant	NULL
action	NULL
of	NULL
NFkB	NULL
inhibition	NULL
was	NULL
sufficient	NULL
to	NULL
paralyze	NULL
the	NULL
T	NULL
cell	NULL
component	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
however	NULL
,	NULL
the	NULL
inflammatory	NULL
infiltrate	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
macrophages	NULL
persisted	NULL
,	NULL
and	NULL
macrophages	NULL
continued	NULL
to	NULL
transcribe	NULL
cytokine	NULL
mRNA	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
T	NULL
cell	NULL
stimulation	NULL
.	NULL

A	NULL
persistent	NULL
activation	NULL
of	NULL
selected	NULL
inflammatory	NULL
cells	NULL
in	NULL
the	NULL
lesions	NULL
would	NULL
explain	NULL
the	NULL
immediate	NULL
relapse	NULL
of	NULL
disease	NULL
activity	NULL
after	NULL
discontinuation	NULL
of	NULL
steroid	NULL
therapy	NULL
.	NULL

GCA	NULL
is	NULL
a	NULL
typical	NULL
example	NULL
of	NULL
a	NULL
chronic	NULL
inflammatory	NULL
disease	NULL
.	NULL

Clinical	NULL
manifestations	NULL
of	NULL
the	NULL
disease	NULL
are	NULL
either	NULL
related	NULL
to	NULL
tissue	NULL
damage	NULL
resulting	NULL
from	NULL
the	NULL
obstruction	NULL
of	NULL
blood	NULL
supply	NULL
because	NULL
of	NULL
occlusion	NULL
of	NULL
inflamed	NULL
arteries	NULL
,	NULL
or	NULL
from	NULL
systemic	NULL
symptoms	NULL
associated	NULL
with	NULL
an	NULL
acute	NULL
phase	NULL
reaction	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
the	NULL
constitutional	NULL
symptoms	NULL
are	NULL
linked	NULL
closely	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
elevated	NULL
levels	NULL
of	NULL
circulating	NULL
IL-6	NULL
(	NULL
17	NULL
)	NULL
.	NULL

IL-6	NULL
is	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
acute-phase	NULL
proteins	NULL
,	NULL
and	NULL
could	NULL
thus	NULL
explain	NULL
the	NULL
principle	NULL
laboratory	NULL
abnormalities	NULL
in	NULL
patients	NULL
diagnosed	NULL
with	NULL
GCA	NULL
(	NULL
18	NULL
)	NULL
.	NULL

IL-6	NULL
is	NULL
produced	NULL
by	NULL
circulating	NULL
monocytes	NULL
as	NULL
well	NULL
as	NULL
by	NULL
tissue-infiltrating	NULL
macrophages	NULL
(	NULL
19	NULL
)	NULL
.	NULL

GCA	NULL
tissue-SCID	NULL
mice	NULL
chimera	NULL
have	NULL
elevated	NULL
serum	NULL
concentrations	NULL
of	NULL
human	NULL
IL-6	NULL
,	NULL
documenting	NULL
that	NULL
even	NULL
a	NULL
small	NULL
fragment	NULL
of	NULL
inflamed	NULL
tissue	NULL
has	NULL
systemic	NULL
effects	NULL
(	NULL
Brack	NULL
,	NULL
A.	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
IL-6	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
NFB	NULL
and	NULL
thus	NULL
should	NULL
be	NULL
subject	NULL
to	NULL
a	NULL
rapid	NULL
immunosuppressive	NULL
action	NULL
of	NULL
glucocorticoids	NULL
,	NULL
it	NULL
can	NULL
be	NULL
predicted	NULL
that	NULL
steroids	NULL
induce	NULL
a	NULL
prompt	NULL
improvement	NULL
.	NULL

Besides	NULL
IL-6	NULL
,	NULL
several	NULL
other	NULL
inflammatory	NULL
cytokines	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
disease	NULL
process	NULL
.	NULL

T	NULL
cells	NULL
accumulated	NULL
in	NULL
the	NULL
arterial	NULL
walls	NULL
display	NULL
a	NULL
stringent	NULL
pattern	NULL
of	NULL
cytokine	NULL
production	NULL
in	NULL
that	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
are	NULL
consistently	NULL
found	NULL
in	NULL
the	NULL
lesions	NULL
.	NULL

TH2	NULL
T	NULL
cell	NULL
type	NULL
cytokines	NULL
such	NULL
as	NULL
IL-4	NULL
or	NULL
IL-5	NULL
are	NULL
not	NULL
detectable	NULL
.	NULL

IFN-y	NULL
appears	NULL
to	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
shaping	NULL
the	NULL
disease	NULL
process	NULL
.	NULL

The	NULL
in	NULL
situ	NULL
IFN-y	NULL
transcription	NULL
has	NULL
been	NULL
related	NULL
to	NULL
the	NULL
development	NULL
of	NULL
full-blown	NULL
vasculitis	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
subclinical	NULL
vascular	NULL
inflammation	NULL
in	NULL
patients	NULL
with	NULL
polymyalgia	NULL
rheumatica	NULL
,	NULL
a	NULL
forme	NULL
fruste	NULL
of	NULL
GCA	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Tissue	NULL
concentrations	NULL
of	NULL
IFN-y	NULL
are	NULL
predictive	NULL
of	NULL
the	NULL
formation	NULL
of	NULL
multinucleated	NULL
giant	NULL
cells	NULL
,	NULL
a	NULL
cell	NULL
population	NULL
which	NULL
has	NULL
been	NULL
assumed	NULL
to	NULL
have	NULL
a	NULL
role	NULL
in	NULL
the	NULL
destruction	NULL
of	NULL
elastic	NULL
tissue	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Patients	NULL
with	NULL
high	NULL
production	NULL
of	NULL
IFN-y	NULL
in	NULL
the	NULL
affected	NULL
arteries	NULL
are	NULL
more	NULL
likely	NULL
to	NULL
develop	NULL
manifestations	NULL
of	NULL
cranial	NULL
arteritis	NULL
with	NULL
blindness	NULL
,	NULL
jaw	NULL
claudication	NULL
,	NULL
and	NULL
central	NULL
nervous	NULL
system	NULL
disease	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
IFN-y	NULL
seems	NULL
to	NULL
act	NULL
as	NULL
a	NULL
cardinal	NULL
amplificator	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

The	NULL
production	NULL
of	NULL
IFN-y	NULL
was	NULL
relatively	NULL
insensitive	NULL
to	NULL
the	NULL
immediate	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
steroids	NULL
,	NULL
possibly	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
an	NULL
NFB	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
IFN-y	NULL
gene	NULL
.	NULL

With	NULL
high	NULL
doses	NULL
of	NULL
steroids	NULL
or	NULL
prolonged	NULL
treatment	NULL
,	NULL
suppression	NULL
of	NULL
IFN-y	NULL
production	NULL
was	NULL
seen	NULL
,	NULL
which	NULL
may	NULL
reflect	NULL
an	NULL
attenuation	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
response	NULL
in	NULL
general	NULL
rather	NULL
than	NULL
a	NULL
direct	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
IFN-y	NULL
transcription	NULL
.	NULL

Inhibition	NULL
of	NULL
IFN-y	NULL
should	NULL
remove	NULL
a	NULL
central	NULL
player	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
and	NULL
it	NULL
would	NULL
be	NULL
expected	NULL
that	NULL
the	NULL
suppression	NULL
of	NULL
IFN-y	NULL
is	NULL
followed	NULL
by	NULL
the	NULL
dis	NULL
appearance	NULL
of	NULL
activated	NULL
macrophages	NULL
.	NULL

This	NULL
progression	NULL
was	NULL
indeed	NULL
the	NULL
case	NULL
for	NULL
the	NULL
production	NULL
of	NULL
IL-1B	NULL
,	NULL
however	NULL
,	NULL
data	NULL
presented	NULL
here	NULL
document	NULL
that	NULL
macrophage	NULL
activation	NULL
persists	NULL
despite	NULL
almost	NULL
complete	NULL
suppression	NULL
of	NULL
IFN-y	NULL
.	NULL

Steroids	NULL
selectively	NULL
inhibited	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
while	NULL
leaving	NULL
TGF-B1	NULL
transcription	NULL
unaffected	NULL
.	NULL

Previous	NULL
data	NULL
have	NULL
suggested	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
steroids	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
TGF-B1	NULL
is	NULL
not	NULL
uniform	NULL
,	NULL
and	NULL
that	NULL
induction	NULL
as	NULL
well	NULL
as	NULL
suppression	NULL
of	NULL
TGF-	NULL
transcription	NULL
,	NULL
can	NULL
be	NULL
found	NULL
dependent	NULL
of	NULL
the	NULL
tissue	NULL
studied	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

The	NULL
persistence	NULL
of	NULL
TGF-B1	NULL
production	NULL
in	NULL
steroid-treated	NULL
GCA	NULL
tissue	NULL
may	NULL
have	NULL
more	NULL
detrimental	NULL
than	NULL
beneficial	NULL
effects	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
microenvironment	NULL
and	NULL
the	NULL
local	NULL
tissue	NULL
concen-trations	NULL
,	NULL
TGF-B	NULL
can	NULL
be	NULL
considered	NULL
as	NULL
an	NULL
anti-	NULL
as	NULL
well	NULL
as	NULL
a	NULL
proinflammatory	NULL
cytokine	NULL
(	NULL
23-27	NULL
)	NULL
.	NULL

TGF-B	NULL
is	NULL
mainly	NULL
produced	NULL
by	NULL
adventitial	NULL
macrophages	NULL
.	NULL

The	NULL
close	NULL
vicinity	NULL
of	NULL
TGF-B	NULL
production	NULL
to	NULL
the	NULL
vasa	NULL
vasorum	NULL
could	NULL
provide	NULL
ideal	NULL
circumstances	NULL
to	NULL
exert	NULL
chemotactic	NULL
activity	NULL
,	NULL
and	NULL
to	NULL
recruit	NULL
macrophages	NULL
into	NULL
the	NULL
inflammatory	NULL
process	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
adventitial	NULL
macrophages	NULL
,	NULL
intimal	NULL
macrophages	NULL
synthesize	NULL
iNOS	NULL
,	NULL
which	NULL
catalyzes	NULL
the	NULL
synthesis	NULL
of	NULL
NO	NULL
.	NULL

iNOS	NULL
production	NULL
in	NULL
the	NULL
inflamed	NULL
arteries	NULL
is	NULL
highly	NULL
sensitive	NULL
to	NULL
steroid-mediated	NULL
repression	NULL
,	NULL
again	NULL
consistent	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
an	NULL
NFB	NULL
binding	NULL
site	NULL
.	NULL

The	NULL
biological	NULL
consequences	NULL
of	NULL
the	NULL
suppression	NULL
of	NULL
NO	NULL
production	NULL
are	NULL
unclear	NULL
.	NULL

NO	NULL
has	NULL
been	NULL
proven	NULL
to	NULL
have	NULL
proinflammatory	NULL
effects	NULL
in	NULL
chronic	NULL
inflammatory	NULL
diseases	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
experimental	NULL
models	NULL
of	NULL
arthritis	NULL
(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
.	NULL

NO	NULL
,	NULL
however	NULL
,	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
inhibiting	NULL
platelet	NULL
adhesion	NULL
and	NULL
smooth	NULL
muscle	NULL
cell	NULL
proliferation	NULL
,	NULL
and	NULL
facilitates	NULL
va-sodilatation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Considering	NULL
that	NULL
NO	NULL
is	NULL
preferentially	NULL
produced	NULL
in	NULL
the	NULL
intima	NULL
,	NULL
and	NULL
that	NULL
many	NULL
clinical	NULL
manifestations	NULL
of	NULL
the	NULL
arteritis	NULL
are	NULL
related	NULL
to	NULL
blood	NULL
vessel	NULL
occlusion	NULL
,	NULL
iNOS	NULL
induction	NULL
could	NULL
serve	NULL
as	NULL
a	NULL
protective	NULL
mechanism	NULL
.	NULL

The	NULL
rapid	NULL
suppression	NULL
by	NULL
steroids	NULL
possibly	NULL
represents	NULL
an	NULL
unwanted	NULL
effect	NULL
of	NULL
the	NULL
therapeutic	NULL
intervention	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
several	NULL
conclusions	NULL
can	NULL
be	NULL
drawn	NULL
from	NULL
the	NULL
analysis	NULL
of	NULL
steroid-treated	NULL
GCA-SCID	NULL
chimeras	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
in	NULL
vitro	NULL
findings	NULL
,	NULL
administration	NULL
of	NULL
steroids	NULL
downregulated	NULL
nuclear	NULL
NFkB	NULL
,	NULL
and	NULL
subsequently	NULL
repressed	NULL
genes	NULL
under	NULL
transcriptional	NULL
control	NULL
of	NULL
NFkB	NULL
.	NULL

While	NULL
the	NULL
suppression	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
might	NULL
have	NULL
a	NULL
beneficial	NULL
outcome	NULL
,	NULL
the	NULL
prompt	NULL
reduction	NULL
in	NULL
iNOS	NULL
might	NULL
actually	NULL
weaken	NULL
protective	NULL
mechanisms	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
high	NULL
doses	NULL
of	NULL
glucocorticoids	NULL
were	NULL
necessary	NULL
to	NULL
accomplish	NULL
blockade	NULL
of	NULL
cytoplasmic	NULL
NFkB	NULL
activation	NULL
by	NULL
IxBa	NULL
and	NULL
the	NULL
subsequent	NULL
inhibition	NULL
of	NULL
cytokine	NULL
synthesis	NULL
.	NULL

These	NULL
doses	NULL
were	NULL
4-40-fold	NULL
higher	NULL
than	NULL
the	NULL
doses	NULL
generally	NULL
recommended	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
GCA	NULL
,	NULL
but	NULL
are	NULL
in	NULL
the	NULL
range	NULL
of	NULL
doses	NULL
used	NULL
for	NULL
in	NULL
vitro	NULL
induction	NULL
of	NULL
IkBa	NULL
transcription	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Although	NULL
it	NULL
appears	NULL
that	NULL
minor	NULL
variations	NULL
in	NULL
cytokine	NULL
concentrations	NULL
already	NULL
have	NULL
significant	NULL
clinical	NULL
conse-quences	NULL
,	NULL
administration	NULL
of	NULL
higher	NULL
steroid	NULL
doses	NULL
in	NULL
the	NULL
early	NULL
treatment	NULL
of	NULL
GCA	NULL
might	NULL
improve	NULL
the	NULL
immunosuppressant	NULL
ef-fect	NULL
.	NULL

Increased	NULL
efficiency	NULL
in	NULL
blocking	NULL
cytokines	NULL
in	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
the	NULL
disease	NULL
may	NULL
reduce	NULL
steroid	NULL
requirements	NULL
in	NULL
the	NULL
long-term	NULL
management	NULL
,	NULL
and	NULL
thus	NULL
reduce	NULL
the	NULL
high	NULL
risk	NULL
for	NULL
GCA	NULL
patients	NULL
to	NULL
develop	NULL
steroid-induced	NULL
side	NULL
effects	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
resistance	NULL
of	NULL
TGF-B1	NULL
production	NULL
to	NULL
steroid	NULL
treatment	NULL
suggests	NULL
that	NULL
TGF-B1+	NULL
macrophages	NULL
appear	NULL
to	NULL
function	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
T	NULL
cell	NULL
stimulatory	NULL
signals	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
TGF-B1	NULL
mRNA	NULL
is	NULL
merely	NULL
an	NULL
indicator	NULL
for	NULL
persistent	NULL
macrophage	NULL
acti-vation	NULL
,	NULL
and	NULL
other	NULL
macrophage-derived	NULL
products	NULL
are	NULL
also	NULL
produced	NULL
in	NULL
the	NULL
vascular	NULL
lesions	NULL
.	NULL

In	NULL
that	NULL
case	NULL
,	NULL
suppressing	NULL
TGF-B1	NULL
activity	NULL
ultimately	NULL
might	NULL
not	NULL
be	NULL
sufficient	NULL
to	NULL
induce	NULL
disease	NULL
re	NULL
mission	NULL
.	NULL

Tissue-residing	NULL
macrophages	NULL
,	NULL
however	NULL
,	NULL
might	NULL
provide	NULL
a	NULL
suitable	NULL
target	NULL
in	NULL
attempts	NULL
to	NULL
complement	NULL
steroid-mediated	NULL
immunosuppression	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Toni	NULL
L.	NULL
Higgins	NULL
for	NULL
outstanding	NULL
secretarial	NULL
assistance	NULL
,	NULL
Dr.	NULL
Johannes	NULL
Bjéornsson	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
and	NULL
Dr.	NULL
Gene	NULL
Hunder	NULL
,	NULL
Division	NULL
of	NULL
Rheumatology	NULL
,	NULL
for	NULL
their	NULL
support	NULL
,	NULL
and	NULL
the	NULL
patients	NULL
who	NULL
donated	NULL
the	NULL
tissue	NULL
to	NULL
make	NULL
these	NULL
studies	NULL
possible	NULL
.	NULL

A.	NULL
Brack	NULL
and	NULL
H.	NULL
Rittner	NULL
were	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Research	NULL
to	NULL
Prevent	NULL
Blindness	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
(	NULL
Research	NULL
to	NULL
Prevent	NULL
Blindness	NULL
No	NULL
.	NULL

3	NULL
)	NULL
and	NULL
the	NULL
Mayo	NULL
Foundation	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Huston	NULL
,	NULL
K.A	NULL
.	NULL

,	NULL
G.G	NULL
.	NULL

Hunder	NULL
,	NULL
J.T	NULL
.	NULL

Lie	NULL
,	NULL
R.H.	NULL
Kennedy	NULL
,	NULL
and	NULL
LR	NULL
.	NULL

Elveback	NULL
.	NULL

1978	NULL
.	NULL

Temporal	NULL
arteritis	NULL
:	NULL
a	NULL
25-year	NULL
epidemiologic	NULL
,	NULL
clinical	NULL
,	NULL
and	NULL
pathologic	NULL
study	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

88:162-167	NULL
.	NULL

2	NULL
.	NULL

Weyand	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
J.	NULL
Schonberger	NULL
,	NULL
U.	NULL
Oppitz	NULL
,	NULL
N.N.H	NULL
.	NULL

Hunder	NULL
,	NULL
K.C	NULL
.	NULL

Hicok	NULL
,	NULL
and	NULL
J.J.	NULL
Goronzy	NULL
.	NULL

1994	NULL
.	NULL

Distinct	NULL
vascular	NULL
lesions	NULL
in	NULL
giant	NULL
cell	NULL
arteritis	NULL
share	NULL
identical	NULL
T	NULL
cell	NULL
clonotypes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:951-960	NULL
.	NULL

3	NULL
.	NULL

Weyand	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
K.C	NULL
.	NULL

Hicok	NULL
,	NULL
G.G	NULL
.	NULL

Hunder	NULL
,	NULL
and	NULL
J.J.	NULL
Goronzy	NULL
.	NULL

1994	NULL
.	NULL

Tissue	NULL
cytokine	NULL
patterns	NULL
in	NULL
polymyalgia	NULL
rheumatica	NULL
and	NULL
giant	NULL
cell	NULL
arteritis	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

121:484-491	NULL
.	NULL

4	NULL
.	NULL

Weyand	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
A.D.	NULL
Wagner	NULL
,	NULL
J.	NULL
Bjornsson	NULL
,	NULL
and	NULL
J.J.	NULL
Goronzy	NULL
.	NULL

1996	NULL
.	NULL

Correlation	NULL
of	NULL
topographical	NULL
arrangement	NULL
and	NULL
the	NULL
functional	NULL
pattern	NULL
of	NULL
tissue-infiltrating	NULL
macrophages	NULL
in	NULL
giant	NULL
cell	NULL
arteritis	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

98:1642-1649	NULL
.	NULL

5	NULL
.	NULL

Wagner	NULL
,	NULL
A.D.	NULL
,	NULL
J.	NULL
Bjornsson	NULL
,	NULL
G.B	NULL
.	NULL

Bartley	NULL
,	NULL
J.J.	NULL
Goronzy	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Weyand	NULL
.	NULL

1996	NULL
.	NULL

Interferon	NULL
gamma	NULL
producing	NULL
T	NULL
cells	NULL
in	NULL
giant	NULL
cell	NULL
vasculitis	NULL
represent	NULL
a	NULL
minority	NULL
of	NULL
tissue	NULL
infiltrating	NULL
cells	NULL
and	NULL
are	NULL
located	NULL
distant	NULL
from	NULL
the	NULL
site	NULL
of	NULL
pathology	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

148:1925-1933	NULL
.	NULL

6	NULL
.	NULL

Yang-Yen	NULL
,	NULL
H.F.	NULL
,	NULL
J.C.	NULL
Chambard	NULL
,	NULL
Y.L	NULL
.	NULL

Sun	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
T.J.	NULL
Schmidt	NULL
,	NULL
J.	NULL
Drouin	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
interference	NULL
between	NULL
c-Jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
mutual	NULL
inhibition	NULL
of	NULL
DNA	NULL
binding	NULL
due	NULL
to	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
.	NULL

Cell	NULL
.	NULL

62:1205-1215	NULL
.	NULL

7	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Rangarajan	NULL
,	NULL
S.	NULL
Kliewer	NULL
,	NULL
L.J	NULL
.	NULL

Ransone	NULL
,	NULL
J.	NULL
Bolado	NULL
,	NULL
N.	NULL
Yang	NULL
,	NULL
LM	NULL
.	NULL

Verma	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Evans	NULL
.	NULL

1990	NULL
.	NULL

Functional	NULL
antagonism	NULL
between	NULL
oncopro-tein	NULL
c-Jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cell	NULL
.	NULL

62:1217-1226	NULL
.	NULL

8	NULL
.	NULL

Jonat	NULL
,	NULL
C.	NULL
,	NULL
H.J	NULL
.	NULL

Rahmsdorf	NULL
,	NULL
K.K	NULL
.	NULL

Park	NULL
,	NULL
A.C.	NULL
Cato	NULL
,	NULL
S.	NULL
Gebel	NULL
,	NULL
H.	NULL
Ponta	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1990	NULL
.	NULL

Antitumor	NULL
promotion	NULL
and	NULL
antiinflammation	NULL
:	NULL
down-modula-tion	NULL
of	NULL
AP-1	NULL
(	NULL
Fos/Jun	NULL
)	NULL
activity	NULL
by	NULL
glucocorticoid	NULL
hormone	NULL
.	NULL

Cell	NULL
.	NULL

62:1189-1204	NULL
.	NULL

9	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
Raptis	NULL
,	NULL
S.S.	NULL
Ahuja	NULL
,	NULL
S.M	NULL
.	NULL

Najjar	NULL
,	NULL
and	NULL
D.T	NULL
.	NULL

Boumpas	NULL
.	NULL

1993	NULL
.	NULL

Negative	NULL
transcription	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
gene	NULL
by	NULL
glucocorticoids	NULL
through	NULL
interference	NULL
with	NULL
nuclear	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91:1481-1489	NULL
.	NULL

10	NULL
.	NULL

Scheinman	NULL
,	NULL
RI	NULL
.	NULL

,	NULL
P.C	NULL
.	NULL

Cogswell	NULL
,	NULL
A.K	NULL
.	NULL

Lofquist	NULL
,	NULL
and	NULL
A.S.	NULL
Baldwin	NULL
.	NULL

1995	NULL
.	NULL

Role	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
IxBa	NULL
in	NULL
mediation	NULL
of	NULL
immunosuppression	NULL
of	NULL
glucocorticoids	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

270:283-286	NULL
.	NULL

11	NULL
.	NULL

Auphan	NULL
,	NULL
N.	NULL
,	NULL
J.A	NULL
.	NULL

DiDonato	NULL
,	NULL
C.	NULL
Rosette	NULL
,	NULL
A.	NULL
Helmberg	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1995	NULL
.	NULL

Immunosuppression	NULL
by	NULL
glucocorticoids	NULL
:	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
activity	NULL
through	NULL
induction	NULL
of	NULL
IkB	NULL
synthesis	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

270:286-290	NULL
.	NULL

12	NULL
.	NULL

Brack	NULL
,	NULL
A.	NULL
,	NULL
V.	NULL
Martinez-Taboada	NULL
,	NULL
J.	NULL
Bjornsson	NULL
,	NULL
BR	NULL
.	NULL

Younge	NULL
,	NULL
CM	NULL
.	NULL

Weyand	NULL
,	NULL
and	NULL
J.J.	NULL
Goronzy	NULL
.	NULL

1995	NULL
.	NULL

Persistence	NULL
of	NULL
giant	NULL
cell	NULL
vasculitis	NULL
in	NULL
xenotransplants	NULL
indicates	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
disease	NULL
relevant	NULL
antigen	NULL
residing	NULL
in	NULL
the	NULL
arterial	NULL
wall	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

38	NULL
:	NULL
$	NULL
404	NULL
(	NULL
Abstr	NULL
.	NULL
)	NULL

.	NULL

13	NULL
.	NULL

Kaltschmidt	NULL
,	NULL
C.	NULL
,	NULL
B.	NULL
Kaltschmidt	NULL
,	NULL
T.	NULL
Henkel	NULL
,	NULL
H.	NULL
Stockinger	NULL
,	NULL
and	NULL
P.A	NULL
.	NULL

Baeuerle	NULL
.	NULL

1995	NULL
.	NULL

Selective	NULL
recognition	NULL
of	NULL
the	NULL
activated	NULL
form	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
by	NULL
a	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Biol	NULL
.	NULL

Chem	NULL
.	NULL

Hoppe-Seyler	NULL
.	NULL

376:9-16	NULL
.	NULL

14	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
B.	NULL
Meier	NULL
,	NULL
D.N	NULL
.	NULL

Minnel	NULL
,	NULL
W.	NULL
Droge	NULL
,	NULL
and	NULL
P.A	NULL
.	NULL

Baeuerle	NULL
.	NULL

1992	NULL
.	NULL

Dithiocarbamates	NULL
as	NULL
potent	NULL
inhibitors	NULL
of	NULL
nuclear	NULL
factor	NULL
kB	NULL
activation	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1181-1194	NULL
.	NULL

15	NULL
.	NULL

Boumpas	NULL
,	NULL
D.	NULL
,	NULL
G.P	NULL
.	NULL

Chrousos	NULL
,	NULL
R.L	NULL
.	NULL

Wilder	NULL
,	NULL
T.R	NULL
.	NULL

Cupps	NULL
,	NULL
and	NULL
J.E	NULL
.	NULL

Balow	NULL
.	NULL

1993	NULL
.	NULL

Glucocorticoid	NULL
therapy	NULL
for	NULL
immune-mediated	NULL
diseases	NULL
:	NULL
basic	NULL
and	NULL
clinical	NULL
correlates	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

119:1198-1208	NULL
.	NULL

16	NULL
.	NULL

Baldwin	NULL
,	NULL
A.S.	NULL
1996	NULL
.	NULL

The	NULL
NFB	NULL
and	NULL
IkB	NULL
proteins-New	NULL
discoveries	NULL
and	NULL
insights	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14:649-683	NULL
.	NULL

17	NULL
.	NULL

Roche	NULL
,	NULL
N.E	NULL
.	NULL

,	NULL
J.W	NULL
.	NULL

Fulbright	NULL
,	NULL
A.D.	NULL
Wagner	NULL
,	NULL
G.G	NULL
.	NULL

Hunder	NULL
,	NULL
J.J.	NULL
Goronzy	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Weyand	NULL
.	NULL

1993	NULL
.	NULL

Correlation	NULL
of	NULL
interleukin-6	NULL
production	NULL
and	NULL
disease	NULL
activity	NULL
in	NULL
polymyalgia	NULL
rheumatica	NULL
and	NULL
giant	NULL
cell	NULL
arteritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

36	NULL
:	NULL
1286-1294	NULL
.	NULL

18	NULL
.	NULL

Yoshizaki	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Kuritani	NULL
,	NULL
and	NULL
T.	NULL
Kishimoto	NULL
.	NULL

1992	NULL
.	NULL

Interleukin-6	NULL
in	NULL
autoimmune	NULL
disorders	NULL
.	NULL

Semin	NULL
.	NULL

Immunol	NULL
.	NULL

4:155-166	NULL
.	NULL

19	NULL
.	NULL

Wagner	NULL
,	NULL
A.D.	NULL
,	NULL
J.J.	NULL
Goronzy	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Weyand	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
profile	NULL
of	NULL
tissue	NULL
infiltrating	NULL
and	NULL
circulating	NULL
CD68*	NULL
cells	NULL
in	NULL
giant	NULL
cell	NULL
arteritis	NULL
.	NULL

Evidence	NULL
for	NULL
two	NULL
components	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94:1134-1140	NULL
.	NULL

Glucocorticoids	NULL
in	NULL
Giant	NULL
Cell	NULL
Arteritis	NULL
2649	NULL
20	NULL
.	NULL

Weyand	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
N.	NULL
Tetzlaff	NULL
,	NULL
J.	NULL
Bjornsson	NULL
,	NULL
and	NULL
J.J.	NULL
Goronzy	NULL
.	NULL

1997	NULL
.	NULL

Disease	NULL
patterns	NULL
and	NULL
tissue	NULL
cytokine	NULL
profiles	NULL
in	NULL
giant	NULL
cell	NULL
arteritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

40:19-26	NULL
.	NULL

21	NULL
.	NULL

AyanlarBatuman	NULL
,	NULL
O.	NULL
,	NULL
A.P	NULL
.	NULL

Ferrero	NULL
,	NULL
A.	NULL
Diaz	NULL
,	NULL
and	NULL
S.A.	NULL
Jimenez	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
transforming	NULL
growth	NULL
factor-beta	NULL
1	NULL
gene	NULL
expression	NULL
by	NULL
glucocorticoids	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88:1574-1580	NULL
.	NULL

22	NULL
.	NULL

Batuman	NULL
,	NULL
O.A	NULL
.	NULL

,	NULL
A.	NULL
Ferrero	NULL
,	NULL
C.	NULL
Cupp	NULL
,	NULL
S.A.	NULL
Jimenez	NULL
,	NULL
and	NULL
K.	NULL
Khalili	NULL
.	NULL

1995	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
beta-1	NULL
gene	NULL
expression	NULL
by	NULL
glucocorticoids	NULL
in	NULL
human	NULL
T	NULL
and	NULL
glial	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:4397-4405	NULL
.	NULL

23	NULL
.	NULL

Wahl	NULL
,	NULL
S.M	NULL
.	NULL

1994	NULL
.	NULL

Transforming	NULL
growth	NULL
factor	NULL
beta	NULL
:	NULL
the	NULL
good	NULL
,	NULL
the	NULL
bad	NULL
,	NULL
and	NULL
the	NULL
ugly	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1587-1590	NULL
.	NULL

24	NULL
.	NULL

Lowrance	NULL
,	NULL
J.H	NULL
.	NULL

,	NULL
FX	NULL
.	NULL

O'Sullivan	NULL
,	NULL
T.E	NULL
.	NULL

Caver	NULL
,	NULL
W.	NULL
Waegell	NULL
,	NULL
and	NULL
H.D	NULL
.	NULL

Gresham	NULL
.	NULL

1994	NULL
.	NULL

Spontaneous	NULL
elaboration	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
suppresses	NULL
host	NULL
defense	NULL
against	NULL
bacterial	NULL
infection	NULL
in	NULL
autoimmune	NULL
MRL/lpr	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1693-1703	NULL
.	NULL

25	NULL
.	NULL

Barral-Netto	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Barral	NULL
,	NULL
C.E	NULL
.	NULL

Brownell	NULL
,	NULL
Y	NULL
.	NULL

A.	NULL
Skeiky	NULL
,	NULL
LR	NULL
.	NULL

Ellingsworth	NULL
,	NULL
D.R	NULL
.	NULL

Twardzik	NULL
,	NULL
and	NULL
S.G.	NULL
Reed	NULL
.	NULL

1992	NULL
.	NULL

Transforming	NULL
growth	NULL
factor-8	NULL
in	NULL
leishmanial	NULL
infection	NULL
:	NULL
a	NULL
parasite	NULL
escape	NULL
mechanism	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

257	NULL
;	NULL
545-548	NULL
.	NULL

26	NULL
.	NULL

Allen	NULL
,	NULL
J.B.	NULL
,	NULL
CL	NULL
.	NULL

Manthey	NULL
,	NULL
A.R	NULL
.	NULL

Hand	NULL
,	NULL
K.	NULL
Ohura	NULL
,	NULL
L.	NULL
Ellingsworth	NULL
,	NULL
and	NULL
2850	NULL
-	NULL
Brack	NULL
et	NULL
al	NULL
.	NULL

S.M	NULL
.	NULL

Wahl	NULL
.	NULL

1990	NULL
.	NULL

Rapid	NULL
onset	NULL
synovial	NULL
inflammation	NULL
and	NULL
hyperplasia	NULL
induced	NULL
by	NULL
transforming	NULL
growth	NULL
factor	NULL
B.	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171:231-247	NULL
.	NULL

27	NULL
.	NULL

Wahl	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
J.B.	NULL
Allen	NULL
,	NULL
G.L	NULL
.	NULL

Costa	NULL
,	NULL
HL	NULL
.	NULL

Wong	NULL
,	NULL
and	NULL
J.R.	NULL
Dasch	NULL
.	NULL

1993	NULL
.	NULL

Reversal	NULL
of	NULL
acute	NULL
and	NULL
chronic	NULL
synovial	NULL
inflammation	NULL
by	NULL
anti-transforming	NULL
growth	NULL
factor	NULL
B.	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177:225-230	NULL
.	NULL

28	NULL
.	NULL

Wahl	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
D.A	NULL
.	NULL

Hunt	NULL
,	NULL
LM	NULL
.	NULL

Wakefield	NULL
,	NULL
N.	NULL
McCartney-Francis	NULL
,	NULL
LM	NULL
.	NULL

Wahl	NULL
,	NULL
A.B	NULL
.	NULL

Roberts	NULL
,	NULL
and	NULL
M.B	NULL
.	NULL

Sporn	NULL
.	NULL

1987	NULL
.	NULL

Transforming	NULL
growth	NULL
factor	NULL
type	NULL
beta	NULL
induces	NULL
monocyte	NULL
chemotaxis	NULL
and	NULL
growth	NULL
factor	NULL
production	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:5788-5792	NULL
.	NULL

29	NULL
.	NULL

Wahl	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
J.B.	NULL
Allen	NULL
,	NULL
B.S	NULL
.	NULL

Weeks	NULL
,	NULL
HL	NULL
.	NULL

Wong	NULL
,	NULL
and	NULL
P.E	NULL
.	NULL

Klotman	NULL
.	NULL

1993	NULL
.	NULL

TGF-B	NULL
enhances	NULL
integrin	NULL
expression	NULL
and	NULL
type	NULL
IV	NULL
collagenase	NULL
secretion	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

90:4577-4581	NULL
.	NULL

30	NULL
.	NULL

McCartney-Francis	NULL
,	NULL
N.	NULL
,	NULL
J.B.	NULL
Allen	NULL
,	NULL
D.E	NULL
.	NULL

Mizel	NULL
,	NULL
J.E	NULL
.	NULL

Albina	NULL
,	NULL
Q.W	NULL
.	NULL

Xie	NULL
,	NULL
C.F	NULL
.	NULL

Nathan	NULL
,	NULL
and	NULL
S.M	NULL
.	NULL

Wahl	NULL
.	NULL

1993	NULL
.	NULL

Suppression	NULL
of	NULL
arthritis	NULL
by	NULL
an	NULL
inhibitor	NULL
of	NULL
nitric	NULL
oxide	NULL
synthase	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:749-754	NULL
.	NULL

31	NULL
.	NULL

Clancy	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
and	NULL
S.B	NULL
.	NULL

Abramson	NULL
.	NULL

1995	NULL
.	NULL

Nitric	NULL
oxide	NULL
.	NULL

A	NULL
novel	NULL
mediator	NULL
of	NULL
inflammation	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

210:93-101	NULL
.	NULL

32	NULL
.	NULL

Luscher	NULL
,	NULL
T.F	NULL
.	NULL

,	NULL
R.R	NULL
.	NULL

Wenzel	NULL
,	NULL
and	NULL
G.	NULL
Noll	NULL
.	NULL

1995	NULL
.	NULL

Local	NULL
regulation	NULL
of	NULL
the	NULL
coronary	NULL
circulation	NULL
in	NULL
health	NULL
and	NULL
disease	NULL
:	NULL
role	NULL
of	NULL
nitric	NULL
oxide	NULL
and	NULL
endothelin	NULL
.	NULL

Eur	NULL
.	NULL

Heart	NULL
.	NULL

J	NULL
.	NULL

16	NULL
(	NULL
Suppl	NULL
.	NULL

C	NULL
)	NULL
:51-58	NULL
.	NULL

